Track market-moving stories before they get noisy

, /PRNewswire/ -- AMH (NYSE: AMH) (the "Company"), a leading large-scale integrated owner, operator and developer of single-family rental homes, today announced that the Board of Trustees declared a dividend of $0.33 per share on the Company's common shares for the second quarter of 2026. The distribution will be payable in cash on June 30, 2026 to shareholders of record on June 15, 2026.

The Board of Trustees also declared a per share quarterly distribution on the Company's cumulative redeemable perpetual preferred shares of $0.36719 per share on the 5.875% Series G shares and $0.39063 per share on the 6.250% Series H shares payable in cash on June 30, 2026 to shareholders of record on June 15, 2026.

About AMH

AMH (NYSE: AMH) is a leading large-scale integrated owner, operator and developer of single-family rental homes. We're an internally managed Maryland real estate investment trust (REIT) focused on developing, renovating, leasing and managing homes as rental properties.

In recent years, we've been named a 2026 Great Place to Work®, a 2026 Top U.S. Homebuilder by Builder100, and one of the 2025 Most Trustworthy Companies in America by Newsweek and Statista Inc. As of March 31, 2026, we owned over 61,000 single-family properties in the Southeast, Midwest, Southwest and Mountain West regions of the United States. Additional information about AMH is available on our website at www.amh.com.

AMH refers to one or more of American Homes 4 Rent, American Homes 4 Rent, L.P. and their subsidiaries and joint ventures. In certain states, we operate under AMH Living or American Homes 4 Rent. Please see www.amh.com/dba to learn more.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that relate to beliefs, expectations or intentions and similar statements concerning matters that are not of historical fact and are generally accompanied by words such as "believe," "expect," "will," "intend," "anticipate" or other words that convey the uncertainty of future events or outcomes. These forward-looking statements include the payment and anticipated timing of the payment of distributions of the Company's common and preferred shares. The Company has based these forward-looking statements on its current expectations and assumptions about future events. While the Company's management considers these expectations to be reasonable, they are inherently subject to risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control and could adversely affect our cash flows and ability to pay distributions. Additional information about these and other important factors that may cause our actual results to differ materially from anticipated results expressed or implied by these forward-looking statements is available in the Company's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement to conform to actual results or changes in expectations, except as required by applicable law.

AMH Contacts

Brian Nelson
Media Relations
Phone: (855) 774-4663
Email: [email protected] 

Nicholas Fromm
Investor Relations
Phone: (855) 794-2447
Email: [email protected] 

SOURCE AMH

, /PRNewswire/ -- AMH (NYSE: AMH) (the "Company"), a leading large-scale integrated owner, operator and developer of single-family rental homes, today announced that members of the Company's management team will participate in a roundtable discussion during Nareit's REITweek 2026 Investor Conference on Wednesday, June 3, 2026 at 11:00 a.m. Eastern Time.

A live audio webcast of the presentation will be available on the Company's website at www.amh.com under "Investor Relations". A replay of the webcast will be available through June 17, 2026.

About AMH

AMH (NYSE: AMH) is a leading large-scale integrated owner, operator and developer of single-family rental homes. We're an internally managed Maryland real estate investment trust (REIT) focused on developing, renovating, leasing and managing homes as rental properties.

In recent years, we've been named a 2026 Great Place to Work®, a 2026 Top U.S. Homebuilder by Builder100, and one of the 2025 Most Trustworthy Companies in America by Newsweek and Statista Inc. As of March 31, 2026, we owned over 61,000 single-family properties in the Southeast, Midwest, Southwest and Mountain West regions of the United States. Additional information about AMH is available on our website at www.amh.com.

AMH refers to one or more of American Homes 4 Rent, American Homes 4 Rent, L.P. and their subsidiaries and joint ventures. In certain states, we operate under AMH Living, AMH Living, LLC, or American Homes 4 Rent. Please see www.amh.com/dba to learn more.

AMH Contacts

Brian Nelson
Media Relations
Phone: (855) 774-4663
Email: [email protected]

Nicholas Fromm
Investor Relations
Phone: (855) 794-2447
Email: [email protected]

SOURCE AMH

American Homes 4 Rent stands out as an internally managed REIT focused on building, owning, and renting single-family homes. AMH maintains high tenant quality, 95% occupancy, and expects 3% rent increases, supporting consistent FFO growth without significant debt or share issuance. Shares trade at 18.76x forward AFFO, below the 10-year average, offering attractive total return potential with a well-covered 4.1% yield and ongoing buybacks.

Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain.

ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source.

Additional analyses being presented at the congress include a pharmacodynamic analysis of TTR knockdown with vutrisiran across subgroups, a pooled safety analysis evaluating the incidence of TTR lowering with vitamin-A-related outcomes across clinical trial and real-world datasets, as well as the design of DemonsTTRate, a global, long-term observational study evaluating real-world use in patients with ATTR-CM.

Presentation Details

Design and Rationale of DemonsTTRate: A Global, Long-Term Observational Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Session: Evolving management of cardiomyopathies: early detection, precision diagnostics, and emerging treatments (Moderated ePosters 3)
Sunday, May 10, 08:30 – 09:15 CEST, 2:30 – 3:15 A.M. EST
Presenting Author: Pablo Garcia-Pavia, Spain

Influence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: Insights From HELIOS-B
Session: Cardiac amyloidosis: therapeutic strategies and clinical outcomes (Moderated ePosters 4)
Sunday, May 10, 15:30 – 16:15 CEST, 9:30 – 10:15 A.M. EST
Presenting Author: Awais Sheikh, United Kingdom

Effect of Vutrisiran in Patients with and without Atrial Fibrillation or Flutter: Analysis from HELIOS-B
Session: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment (Moderated ePosters 2)
Monday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST
Presenting Author: Xiaowen Wang, United States of America

Treatment with Transthyretin-Lowering RNA Interference Therapeutics is Not Associated with Ocular or Other Clinical Events Due to Vitamin A Reduction: Pooled Analysis of Vutrisiran and Patisiran Data
Session: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment (Moderated ePosters 2)
Monday, May 11, 10:30 – 11:15 CEST, 4:30 – 5:15 A.M. EST
Presenting Author: Mathew Maurer, United States of America

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with Transthyretin Amyloidosis
Session: Transthyretin amyloidosis: long-term outcomes and emerging therapies (Rapid Fire Abstracts)
Monday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST
Presenting Author: Vincent Algalarrondo, France

Influence of Disease-Modifying Therapy on the Effectiveness of Vutrisiran in Transthyretin Cardiac Amyloidosis
Session: Transthyretin amyloidosis: long-term outcomes and emerging therapies (Rapid Fire Abstracts)
Monday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST
Presenting Author: Arielle Abovich, United States of America

Consistent Efficacy of Vutrisiran Across Sexes in ATTR-CM, HELIOS-B Trial –Prespecified Sex Analysis
Session: Transthyretin amyloidosis: long-term outcomes and emerging therapies (Rapid Fire Abstracts)
Monday, May 11, 16:45 – 17:45 CEST, 10:45 – 11:45 A.M. EST
Presenting Author: Josephine Mansell, United Kingdom

Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial
Session: Risk factors and comorbidities (Moderated ePosters 3)
Tuesday, May 12, 08:30 to 09:15 CEST, 2:30 – 3:15 A.M. EST
Presenting Author: Sarah Birkhoelzer, United Kingdom

AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications
In the EU, AMVUTTRA® (vutrisiran) is indicated for the treatment of:

hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Availability across the EU is subject to local reimbursement timelines.

Important Safety Information
Reduced Serum Vitamin A Levels and Recommended Supplementation
Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions
Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.

For additional information about vutrisiran, please see the full Summary of Product Characteristics.

About AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran) is a transthyretin (TTR) silencer that delivers rapid knockdown of TTR at the source to address the underlying cause of transthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. It is approved as a treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries, globally. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only silencer approved for the treatment of ATTR-CM and hATTR-PN.

About Transthyretin Amyloidosis (ATTR)
Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR.

About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.

Alnylam Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; and Alnylam’s ability to execute on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its “Alnylam 2030” strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

More News From Alnylam Pharmaceuticals, Inc.

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –

− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –

− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM −

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-CM that is designed to deliver rapid knockdown of TTR at the source. The data presented at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology, show consistent clinical benefit across patient populations commonly encountered in clinical practice, including those with a high disease burden, supporting its use as a first-line treatment option for this rapidly progressive and life-threatening disease.

“The analyses presented at Heart Failure 2026 provide important insights into how vutrisiran performs across the patients we see in clinical practice, including those who present with features such as atrial fibrillation, low systolic blood pressure and a high comorbidity burden,” said Scott Solomon, M.D., Professor of Medicine at Harvard Medical School and cardiologist at Brigham and Women’s Hospital. “These new HELIOS-B analyses show that the clinical benefits of vutrisiran were maintained across these clinically complex patient groups, as well as in patients receiving background therapies, including TTR stabilizers and disease-modifying heart failure therapies, reinforcing both the consistency of the treatment effect and its relevance in real-world clinical practice. Taken together, these findings support the use of vutrisiran as a first-line treatment option for ATTR-CM across a broad range of patient populations.”

In patients with atrial fibrillation, representing approximately 65% of the HELIOS-B study population and associated with more advanced disease, vutrisiran significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo. Treatment effects were also maintained in patients with low systolic blood pressure (SBP), a higher-risk phenotype, with vutrisiran slowing the progressive decline in SBP observed over time. Clinical benefits were similarly consistent regardless of comorbidity burden or concomitant use of disease-modifying therapies, including tafamidis and heart failure medications such as SGLT2 inhibitors, MRAs, ß-blockers and ACEi/ARB/ARNI. Consistent effects were also observed in women, a historically underrepresented population in ATTR-CM trials.

A separate pooled analysis of clinical trial and post-marketing safety data evaluated the relationship between transthyretin-lowering RNAi therapies and vitamin A deficiency-related adverse events. Patients treated with vutrisiran and patisiran are suggested to take the recommended daily allowance of vitamin A. The analysis included more than 25,000 patient-years of treatment exposure across vutrisiran and patisiran programs. Rates of ocular adverse events potentially associated with vitamin A deficiency were low and comparable to placebo. No cases of clinically meaningful vitamin A deficiency were observed.

“Vitamin A plays an essential role in vision and other key physiological functions. While transthyretin contributes to its transport, multiple pathways support its delivery throughout the body,” said William S. Blaner, Ph.D., Professor of Nutritional Medicine at Columbia University and expert in vitamin A metabolism and transport. “The low and comparable to placebo rates of vitamin A deficiency-related adverse events observed in this large analysis provide strong reassurance that lowering transthyretin does not meaningfully increase these events in patients with ATTR amyloidosis.”

Alnylam also presented the design and rationale of the DemonsTTRate study, a global, prospective, observational study evaluating real-world outcomes in patients with ATTR-CM. The study is expected to enroll more than 2,000 patients and follow them for up to five years, generating longitudinal data on clinical outcomes, treatment patterns and healthcare utilization across routine clinical practice.

Across ATTR-CM and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN), worldwide experience with vutrisiran to date exceeds 13,000 patient-years, reflecting a robust and expanding body of clinical evidence across both manifestations of the disease. To view Alnylam’s Heart Failure 2026 presentations please visit Capella.

AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications

In the EU, AMVUTTRA® (vutrisiran) is indicated for the treatment of:

hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Availability across the EU is subject to local reimbursement timelines.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.

For additional information about vutrisiran, please see the full Summary of Product Characteristics.

About AMVUTTRA® (vutrisiran)

AMVUTTRA® (vutrisiran) is a transthyretin (TTR) silencer that delivers rapid knockdown of TTR at the source to address the underlying cause of transthyretin amyloidosis (ATTR). In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. It is approved as a treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in various countries, globally. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only silencer approved for the treatment of ATTR-CM and hATTR-PN.

About Transthyretin Amyloidosis (ATTR)

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects, including, without limitation, statements regarding the potential for vutrisiran to be used as a first-line treatment for ATTR-CM; the potential efficacy of vutrisiran in patients who present with features such as atrial fibrillation, low systolic blood pressure and a high comorbidity burden; the number of patients who will be enrolled in the DemonsTTRate study, the duration of the follow-up period for those patients, and the data the study will generate; and Alnylam’s ability to execute on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its “Alnylam 2030” strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

More News From Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

-

− Collaboration is valued at up to $2B with upfront consideration of $30M −

− Alliance pairs Alnylam’s RNAi platform and 20+ years of proprietary data with Inceptive’s foundation models and AI expertise to catalyze progress beyond rational drug design –

− Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs −

CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash and the purchase of Inceptive equity. Inceptive is eligible to receive additional payments based on the achievement of preclinical, regulatory, and commercial sales milestones.

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Share By integrating Inceptive’s generative AI models with Alnylam’s R&D engine, Alnylam aims to accelerate the discovery of novel RNAi therapeutics as it advances ambitious pipeline expansion goals as part of its Alnylam 2030 strategy.

“We’re thrilled to partner with Inceptive to push the boundaries of what is possible in the discovery of RNAi medicines,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “Inceptive stands apart as one of the most visionary companies working at the intersection of AI and biology. It is led by pioneers of the AI revolution and driven by an ambitious mission to fundamentally reinvent how RNA medicines are designed. Together, we have an extraordinary opportunity to accelerate the creation of transformative medicines with a speed, ingenuity, and sophistication that simply has not been possible before.”

Inceptive’s foundation model learns the patterns underlying biology and hence can adapt to diverse therapeutic modalities without retraining. In joint exploratory work, the model achieved exceptional performance within weeks, uncovering meaningful biological insights from relatively small datasets to characterize siRNA molecules, the active ingredient in RNAi therapeutics.

"Most drug design still works through a process of trial and error, testing thousands of molecules and hoping something sticks,” said Jakob Uszkoreit, Inceptive co-founder and CEO. “Inceptive was built on a different premise: that life follows rules of such complexity that only AI can learn them. Alnylam’s breakthrough platform and scientific vision are an ideal match for AI. Together, we’re not just accelerating drug discovery; we’re changing the way we understand and improve life.”

Generalizable Platforms Open New Therapeutic Design Spaces

The collaboration pairs Alnylam’s RNAi leadership with Inceptive’s foundation models and AI expertise to catalyze and accelerate progress in nucleic-acid based drug design. Inceptive focuses on developing models for sequence-based medicines such as RNAi therapeutics, which were pioneered by Alnylam.

Alnylam’s platform: An R&D engine that has produced six approved drugs, backed by 20+ years of proprietary siRNA data. Inceptive’s foundation models of life: AI models for sequence-based medicines that generalize across programs and continuously improve. The collaboration seeks to advance siRNA design, by modeling target mRNAs and jointly exploring sequence space and novel chemical modifications to enhance potency and efficacy, and by predicting top-performing therapeutic candidates in preclinical models for further development by Alnylam. The goal is to help Alnylam prioritize the most promising molecules and improve experimental productivity.

By combining Alnylam’s deep biological expertise with Inceptive’s frontier models, the alliance advances Alnylam’s ambition to unlock new therapeutic innovation through frontier AI. The collaboration gives Alnylam access to Inceptive’s AI expertise and talent, including CEO Jakob Uszkoreit, co-inventor of the Transformer architecture (i.e., the “T” in ChatGPT), and pioneers of scalable, AI-enabled wet-lab training data generation methods.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

About Inceptive

Inceptive builds AI foundation models of life that extrapolate from data to design breakthrough biological medicines beyond the reach of nature and traditional drug discovery. The company’s antedisciplinary team of AI researchers, biochemists, and engineers trains models on diverse biological data and designs experiments to generate missing training data at unprecedented scale. Inceptive partners with leading drugmakers to customize molecule-design models for discovery of sequence-based medicines such as siRNA, ASOs, peptides, and mRNA for applications such as in-vivo cell therapies. Founded in 2021 and backed by a16z, NVIDIA, S32 and Obvious, Inceptive is headquartered in Palo Alto with offices in Berlin and Zurich. Learn more at inceptive.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding the potential for Alnylam’s collaboration with Inceptive to achieve the goals for which it was established, including to increase the pace of therapeutic innovation, to catalyze and accelerate progress in nucleic-acid based drug design, accelerate timelines and unlock innovative oligonucleotide designs, and to accelerate the creation of transformative medicines with a speed, ingenuity and sophistication that has not been possible before; Alnylam’s ability to accelerate the discovery of novel RNAi therapeutics and to push the boundaries of what is possible in the discovery of RNAi medicines; and Alnylam’s ability to achieve the goals in its Alnylam 2030 strategy should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

More News From Alnylam Pharmaceuticals, Inc. and Inceptive

Back to Newsroom

The partnership aims to enhance the discovery of RNA interference (RNAi) therapeutics by integrating Alnylam’s RNAi platform with Inceptive’s AI expertise, potentially accelerating timelines for innovative drug designs.

Alnylam aims to accelerate the discovery of novel RNAi therapeutics as it advances ambitious pipeline expansion goals as part of its Alnylam 2030 strategy.

Alnylam and Inceptive Nucleics CollaborationThe collaboration is valued at up to $2 billion, with an upfront consideration of $30 million, including cash and equity.

By combining their strengths, Alnylam and Inceptive aim to unlock new therapeutic designs and improve the productivity of experimental processes.

ALNY Technical Analysis: Trend, RSI And Key SupportCurrently, Alnylam’s stock price is $296.00, which places it about 0.5% above its 20-day simple moving average (SMA) of $294.61.

The stock is trading 3.8% below its 50-day SMA of $307.82, indicating a bearish trend as the 20-day SMA is below the 50-day SMA, suggesting potential resistance at higher levels.

The Relative Strength Index (RSI) is at 46.01, indicating neutral momentum, suggesting that the stock is neither overbought nor oversold at this time.

This neutral reading implies that there may be room for movement in either direction, depending on upcoming catalysts or market conditions.

Key Resistance: $317.50 — a nearby level where rebounds can stall, closely tied to recent pivot zones. Key Support: $284.50 — a level where buyers previously stepped in, aligning with the 52-week low zone. Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $438.47. Recent analyst moves include:

Citigroup: Initiated with Buy (Target $380.00) (May 19) HC Wainwright & Co.: Buy (Maintains Target to $510.00) (May 5) RBC Capital: Outperform (Lowers Target to $445.00) (May 1) How Alnylam (ALNY) Ranks On Value And MomentumBelow is the Benzinga Edge scorecard for Alnylam Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

Value: 6.83 — The stock is trading at a premium relative to peers. Momentum: 10.33 — Indicates strong upward price movement in recent sessions. The Verdict: Alnylam Pharmaceuticals’s Benzinga Edge signal reveals a growth-heavy profile, with strong momentum but a premium valuation. This suggests that while the stock is performing well, it may be priced for continued success in the market.

ALNY Top ETF Holdings And Passive Flow ExposureALNY Stock Price Activity: Alnylam Pharmaceuticals shares were up 1.79% at $297.81 at the time of publication on Thursday, according to Benzinga Pro data.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Alnylam Stock Soars 65%: Find Out What’s Behind the GainsAlnylam Pharmaceuticals NASDAQ: ALNY executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter.

Jeff Poulton, Alnylam’s chief financial officer, said the company’s “Alnylam 2030” plan is its fourth set of five-year goals and is intended to clarify priorities for both investors and employees. The plan calls for a 25% compound annual growth rate in total revenue, including product sales, collaboration revenue and royalty revenue, as well as a 30% non-GAAP operating margin across the period.

Get ALNY alerts:

3 biotech powerhouses poised to thrive amid sector reboundPoulton said Alnylam is defining leadership in TTR by both peak franchise revenue in 2030 and cumulative revenue over the five-year period. He said AMVUTTRA is expected to be the primary TTR revenue driver through 2030, given the timing of nucresiran’s phase 3 studies. Poulton said Alnylam expects the nucresiran polyneuropathy study could support market entry around 2028, while cardiomyopathy is more likely around 2030.

“For 2030, that’s primarily going to be AMVUTTRA,” Poulton said, referring to the company’s TTR revenue contribution. He added that nucresiran could become a more important growth and margin driver after 2030 if it achieves the profile Alnylam expects.

Margin Targets Reflect Royalty Burden and R&D Spending Argenx's 28% Surge & Promising Product Propel Investor ConfidencePoulton said the company’s 30% non-GAAP operating margin target was below where market expectations had been, noting that consensus had been closer to 50% operating margins in 2030. He said the company’s gross margin profile is affected by the AMVUTTRA royalty burden, with market consensus around 75% gross margins.

Alnylam also plans to invest heavily in research and development to diversify beyond TTR. Poulton said the company is targeting R&D reinvestment of about 30% of revenue across the period, including capacity for business development.

Pushkal Garg, Alnylam’s head of development, said the company’s primary focus will remain its internal pipeline, which includes about 25 drugs in development and an expected three or four new investigational new drug applications each year. He said Alnylam will consider external opportunities, but only with a “very high bar,” emphasizing early-stage assets that advance delivery objectives or fit with the company’s commercial footprint.

AMVUTTRA Launch and TTR Market Expansion Poulton said Alnylam’s revenue guidance for the year is $4.4 billion to $4.7 billion. He said first-quarter performance was affected by phasing issues in both the U.S. and international markets, including insurance reauthorization in January, fewer shipping Wednesdays compared with the fourth quarter and a German pricing adjustment tied to cardiomyopathy launch dynamics. He said those factors are not expected to affect the rest of the year.

In the U.S., Poulton said Alnylam has achieved more than 90% first-line patient access to AMVUTTRA from a payer perspective. He said the company is focused on expanding the prescriber base and improving diagnosis, including through a partnership with Viz.ai to use an artificial intelligence algorithm connected to electronic health records to review echocardiogram tests in five health networks.

Poulton said Alnylam estimates the TTR opportunity at 200,000 or more patients in the U.S. and 500,000 or more globally, with about 20% of the prevalent population currently treated. Garg said he expects the silencer class to become foundational therapy, beginning with AMVUTTRA and potentially followed by nucresiran, which he described as a twice-yearly drug targeting 95% knockdown.

Nucresiran and Combination Therapy On nucresiran’s cardiomyopathy study, Garg said it is largely designed as a combination therapy trial, with many patients expected to be on background stabilizer therapy. He said Alnylam used patient-level data from HELIOS-B to understand event rates and trial design. Garg also said enrollment has been ahead of schedule and that patients appear somewhat milder than those in HELIOS-B, prompting the company to use a predefined option to increase sample size by 500 patients.

Poulton said Alnylam has seen some AMVUTTRA and tafamidis combination use, primarily in the Medicare fee-for-service market, where payer management is less restrictive. He said combination use is generally restricted in the commercial and Medicare Advantage segments. Poulton added that a larger opportunity for combination therapy could emerge when tafamidis becomes generic, which he said is expected in the middle of 2031 based on Pfizer’s recently announced settlements.

Near-Term Pipeline Readouts Garg highlighted several programs expected to generate data in the near term. In metabolic disease, Alnylam’s ACVR1C, or ALK7, program targets adipose tissue and is intended to reduce visceral fat while preserving muscle mass. Garg said the obesity and overweight market is likely to segment over time, creating possible roles for the drug as monotherapy or in combination with other agents.

In Huntington’s disease, Garg said Alnylam’s program targets both full-length mutant huntingtin and the exon 1 fragment, which he said is viewed by many academics as important in the propagation of huntingtin aggregates. He said the company hopes to show high levels of knockdown, infrequent dosing and favorable safety data later this year, potentially supporting movement into pivotal trials.

Garg also discussed a plasminogen-targeting program that could act as a universal hemostatic agent by stabilizing clots without increasing thrombosis risk, based on genetic and preclinical data. Alnylam’s first indication is hereditary hemorrhagic telangiectasia, with bleed data expected later this year. The company has also initiated work in von Willebrand disease and heavy menstrual bleeding.

In central nervous system disease, Garg said mivelsiran targets amyloid precursor protein and is being studied in early-onset Alzheimer’s disease and cerebral amyloid angiopathy. He said enrollment completion in the CAA study is targeted for the second quarter, with data expected in late 2027 or early 2028. Alnylam is also advancing a tau-targeting siRNA in phase 1 development.

About Alnylam Pharmaceuticals NASDAQ: ALNYAlnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory.

The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo. This latest strategic expansion reinforces both companies’ shared commitment to improving patient access to innovative therapies across Europe, particularly in regions where unmet medical needs remain significant.

Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam Pharmaceuticals stated: “We are proud of our strong and established partnership with GENESIS Pharma and are delighted to broaden this across the Nordic region. Our commitment is to deliver transformational impact for patients across the world. By working alongside GENESIS Pharma, we can continue to address the needs of even more patients and their families, enabling them to benefit from Alnylam’s innovative RNAi therapeutics.”

Constantinos Evripides, Managing Director of GENESIS Pharma stated: “Since 2019, we have been working closely with Alnylam to ensure patient access across Southeast Europe. The expansion in the Nordic countries marks a significant milestone in our partnership and reflects our ongoing efforts to strengthen our European footprint, building on our three-decade legacy and commitment to biotechnology. By combining Alnylam’s pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems. We are honored by the trust Alnylam has placed in our company and our people.”

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.1 Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.2 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made.1 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About GENESIS Pharma

GENESIS Pharma is a European biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases, currently covering 24 countries in Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in the region to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.

REFERENCES

1 Elbashir SM, Harborth J, Lendeckel W, et al. Nature. 2001;411(6836):494-498.

2 Zamore P. Cell. 2006;127(5):1083-1086.

Key Takeaways ALNY's Amvuttra generated $889.9M in Q1 2026 sales, up 187% year over year, comprising 76% of total revenues.ALNY won U.S. and EU approval to expand Amvuttra into ATTR-CM, broadening eligible patients.ALNY faces ATTR-CM competition from Pfizer's Vyndaqel/Vyndamax and BridgeBio's Attruby. Alnylam Pharmaceuticals (ALNY - Free Report) is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approval for Givlaari (acute hepatic porphyria), Oxlumo (primary hyperoxaluria type 1) and Amvuttra (polyneuropathy of hATTR amyloidosis).

In 2025, Alnylam received approval in the United States and the EU for the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. Following the label expansion, Amvuttra became the first and only RNAi therapeutic approved in the United States and the EU for both ATTR-CM and hATTR-PN in adults, marking a significant milestone.

Currently, Amvuttra (vutrisiran), its newest drug, is Alnylam’s primary top-line driver. The drug generated $889.9 million in global sales in the first quarter of 2026, representing 187% year-over-year growth. The figure accounted for 76% of Alnylam’s total revenues generated in the quarter. The drug’s solid uptake has been driven by increased patient demand, mainly in ATTR-CM patients in the United States, as well as several patients switching from Onpattro.

This label expansion is expected to continue boosting Amvuttra sales in the quarters ahead. Alnylam also expects approvals for Amvuttra for the ATTR-CM indication in other geographies this year. This will expand the eligible patient population for the drug, driving substantial growth for the company in the future.

ALNY’s Competition in the Market for ATTR TreatmentsAlnylam’s Amvuttra faces notable competition in the ATTR-CM market from Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), both of which are already approved for this indication. While Amvuttra is positioned with a differentiated clinical profile, Pfizer’s and BridgeBio’s therapies carry the advantage of oral administration and comparatively lower list prices in the United States. These factors could influence prescribing decisions and pose challenges to Alnylam’s competitive positioning in this space.

Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first quarter of 2026. Global Vyndaqel family revenues of $1.6 billion rose 8% year over year in the quarter, primarily driven by international growth on the back of higher demand due to increases in diagnosis and treatment rates. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.

Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $180.6 million in the first quarter of 2026, up significantly year over year, driven by solid uptake. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.

ALNY’s Stock Price, Valuation and EstimatesShares of Alnylam have plunged 27.3% so far this year compared with the industry’s 4% decline. The stock has also underperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.

ALNY Stock Price MovementImage Source: Zacks Investment Research

From a valuation standpoint, Alnylam stock is expensive. Going by the price/sales ratio, the company’s shares currently trade at 9.33 trailing 12-month sales per share, higher than 2.25 for the industry. However, the stock is also trading much below its five-year mean of 18.40.

ALNY Stock ValuationImage Source: Zacks Investment Research

Estimates for Alnylam’s 2026 earnings have improved from $9.13 to $9.22 per share in the past 60 days, while the estimates for 2027 earnings have deteriorated from $14.59 to $13.68 over the same timeframe.

ALNY Estimate MovementImage Source: Zacks Investment Research

Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Consumer Staples group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Archer Daniels Midland (ADM - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.

Archer Daniels Midland is a member of our Consumer Staples group, which includes 173 different companies and currently sits at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Archer Daniels Midland is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for ADM's full-year earnings has moved 4.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that ADM has returned about 20.4% since the start of the calendar year. In comparison, Consumer Staples companies have returned an average of 4.3%. This means that Archer Daniels Midland is outperforming the sector as a whole this year.

Another Consumer Staples stock, which has outperformed the sector so far this year, is Post Holdings (POST - Free Report) . The stock has returned 4.6% year-to-date.

Over the past three months, Post Holdings' consensus EPS estimate for the current year has increased 3.2%. The stock currently has a Zacks Rank #2 (Buy).

Breaking things down more, Archer Daniels Midland is a member of the Agriculture - Operations industry, which includes 11 individual companies and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 16.5% this year, meaning that ADM is performing better in terms of year-to-date returns.

On the other hand, Post Holdings belongs to the Food - Miscellaneous industry. This 41-stock industry is currently ranked #182. The industry has moved -4.1% year to date.

Investors interested in the Consumer Staples sector may want to keep a close eye on Archer Daniels Midland and Post Holdings as they attempt to continue their solid performance.

Key Takeaways Post Holdings' Foodservice segment likely drove Q2 on value-added eggs and steady demand.Post Holdings might benefit from cereal productivity and cost-saving initiatives.Cereal softness and weak dog food demand remained headwinds in the quarter. Post Holdings, Inc. (POST - Free Report) is set to unveil its second-quarter fiscal 2026 results on May 7, after market close. Investors are eager to see if the company can beat market expectations.

The Zacks Consensus Estimate for revenues is pegged at $2.1 billion, implying 5.6% growth from the prior year. 

Meanwhile, the consensus mark for earnings per share has been unchanged at $1.64 over the past seven days, suggesting 16.3% growth from the year-ago period. POST has a trailing four-quarter earnings surprise of 19.6%, on average.

Key Factors to Note for POST's Q2 EarningsPost Holdings’ fiscal second-quarter 2026 performance is likely to have benefited from continued strength in its Foodservice segment, supported by resilient demand for value-added egg products and favorable customer trends. The Zacks Consensus Estimate for Foodservice net sales is pegged at $633 million, indicating growth of 4.1% from the year-ago reported figure.

At its first-quarter fiscal 2026 earnings call, management highlighted that customer inventory reloads had largely been completed and indicated confidence in sustaining normalized growth trends in the future. Foodservice may have continued to benefit from its labor-saving value proposition, as operators shift toward value-added egg offerings to reduce labor needs.

Within Post Consumer Brands, the pet food business is likely to have witnessed some benefit from tested price points. Additionally, expanding private-label offerings in dinner sides, including mashed potatoes and macaroni & cheese, are expected to have supported volumes while improving capacity utilization across the network. The Zacks Consensus Estimate for net sales in the Post Consumer Brands segment is pegged at $1,059 million, indicating 7.2% growth from the year-ago reported figure.

POST may have had some operational benefit from productivity initiatives and cost-saving actions within its cereal operations, though management said the main benefits from cereal plant closures should flow through the profit-and-loss statement starting in the third quarter and fourth quarter of fiscal 2026.

However, some headwinds are likely to have persisted during the quarter. Management previously noted that Foodservice inventory-related benefits would normalize sequentially following the strong first quarter. In addition, cereal category trends are likely to have remained soft. The company is likely to have faced softer demand trends in dog food, which might have weighed on overall performance.

What the Zacks Model Says About POST’s Q2 EarningsOur proven model does not conclusively predict an earnings beat for POST this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here.

POST has an Earnings ESP of -4.27% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks With Favorable CombinationHere are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:

Shake Shack, Inc. (SHAK - Free Report) has an Earnings ESP of +19.41% and currently carries a Zacks Rank of 3. The Zacks Consensus Estimate for fourth-quarter fiscal 2025 earnings per share is pegged at 11 cents, implying a 21.4% year-over-year decline. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for quarterly revenues is pegged at $371.4 million, which indicates an increase of 15.8% from the figure reported in the prior-year quarter. SHAK has a trailing four-quarter earnings surprise of 6.3%, on average.

Celsius Holdings, Inc. (CELH - Free Report) currently has an Earnings ESP of +3.81% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter fiscal 2026 earnings per share is pegged at 29 cents, implying a 61.1% year-over-year surge.

The Zacks Consensus Estimate for quarterly revenues is pegged at $755.2 million, which indicates an increase of 129.4% from the figure reported in the prior-year quarter. CELH has a trailing four-quarter earnings surprise of 45.3%, on average.

Lamb Weston Holdings, Inc. (LW - Free Report) currently has an Earnings ESP of +1.87% and a Zacks Rank of 3. The Zacks Consensus Estimate for fourth-quarter fiscal 2026 earnings per share is pegged at 61 cents, implying a 29.9% year-over-year decline.

The Zacks Consensus Estimate for quarterly revenues is pegged at $1.7 billion, which indicates growth of 1% from the figure reported in the prior-year quarter. LW has a trailing four-quarter earnings surprise of 23.5%, on average.

, /PRNewswire/ -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the second fiscal quarter ended March 31, 2026.

Highlights:

Second quarter net sales of $2.0 billion Operating profit of $211.9 million; net earnings of $81.9 million and Adjusted EBITDA (non-GAAP)* of $395.0 million Affirmed fiscal year 2026 Adjusted EBITDA (non-GAAP)* outlook of $1,550-$1,580 million *For additional information regarding non-GAAP measures, such as Adjusted EBITDA, Adjusted net earnings, Adjusted diluted earnings per common share and segment Adjusted EBITDA, see the related explanations presented under "Use of Non-GAAP Measures" later in this release. Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including the adjustments described under "Outlook" below.

Basis of Presentation

On July 1, 2025, Post completed its acquisition of 8th Avenue Food & Provisions, Inc. ("8th Avenue"), the results of which are included in the Post Consumer Brands segment. On December 1, 2025, Post completed its sale of the pasta business of 8th Avenue; its operating results prior to the sale were reported in the Post Consumer Brands segment.

On March 3, 2025, Post completed its acquisition of Potato Products of Idaho, L.L.C. ("PPI"), the results of which are included in the Refrigerated Retail and Foodservice segments.

Second Quarter Consolidated Operating Results

Net sales were $2,042.9 million, an increase of 4.7%, or $90.8 million, compared to $1,952.1 million in the prior year period and included $152.3 million in net sales from acquisitions in the current year period. Excluding the benefit from acquisitions in the current year period, net sales declines in Post Consumer Brands (driven by pet food distribution losses and the lapping of customer inventory shifts) were partially offset by growth in Foodservice (primarily driven by volume growth in eggs and protein-based shakes), Refrigerated Retail (driven by new product introductions and the shifting of Easter demand into the quarter) and Weetabix (driven by favorable foreign currency exchange rates). Gross profit was $617.6 million, or 30.2% of net sales, an increase of 13.2%, or $71.8 million, compared to $545.8 million, or 28.0% of net sales, in the prior year period.

Selling, general and administrative ("SG&A") expenses were $326.2 million, or 16.0% of net sales, an increase of 3.6%, or $11.4 million, compared to $314.8 million, or 16.1% of net sales, in the prior year period. Operating profit was $211.9 million, an increase of 16.3%, or $29.7 million, compared to $182.2 million in the prior year period. Operating profit in the second quarter of fiscal year 2026 included a loss on amounts held for sale of $28.3 million related to Crystal Farms Dairy Company, which was treated as an adjustment for non-GAAP measures.

Net earnings were $81.9 million, an increase of 30.8%, or $19.3 million, compared to $62.6 million in the prior year period.

Diluted earnings per common share were $1.56, compared to $1.03 in the prior year period. Adjusted net earnings (non-GAAP)* were $104.7 million, compared to $88.7 million in the prior year period. Adjusted diluted earnings per common share (non-GAAP)* were $1.94, compared to $1.41 in the prior year period.

Adjusted EBITDA was $395.0 million, an increase of 14.0%, or $48.5 million, compared to $346.5 million in the prior year period.

Six Month Consolidated Operating Results

Net sales were $4,217.5 million, an increase of $290.7 million, compared to $3,926.8 million in the prior year period. Gross profit was $1,256.1 million, or 29.8% of net sales, an increase of 10.1%, or $115.0 million, compared to $1,141.1 million, or 29.1% of net sales, in the prior year period.

SG&A expenses were $683.5 million, or 16.2% of net sales, an increase of 5.7%, or $37.1 million, compared to $646.4 million, or 16.5% of net sales, in the prior year period. Operating profit was $450.3 million, an increase of 13.6%, or $54.0 million, compared to $396.3 million in the prior year period.

Net earnings were $178.7 million, an increase of 1.6%, or $2.8 million, compared to $175.9 million in the prior year period. Net earnings included the following:

Six Months Ended March 31,

(in millions)

2026

2025

Loss on extinguishment of debt, net (1)

$            17.5

$             5.8

Income on swaps, net (1)

(3.6)

(9.9)

(1) Discussed later in this release and were treated as adjustments for non-GAAP measures.

Diluted earnings per common share were $3.28, compared to $2.83 in the prior year period. Adjusted net earnings were $228.5 million, compared to $200.7 million in the prior year period. Adjusted diluted earnings per common share were $4.07, compared to $3.13 in the prior year period.

Adjusted EBITDA was $813.2 million, an increase of 13.5%, or $96.8 million, compared to $716.4 million in the prior year period.

Post Consumer Brands

Primarily North American ready-to-eat ("RTE") cereal and granola, pet food and nut butters.

For the second quarter, net sales were $1,044.9 million, an increase of 5.8%, or $57.0 million, compared to the prior year period. Net sales included $145.0 million in the second quarter attributable to 8th Avenue. Excluding the benefit of 8th Avenue in the current year period, volumes decreased 10.0% as pet food volumes declined 14.1% and cereal and granola volumes declined 3.5%. Pet food volume losses were primarily driven by distribution losses and the lapping of customer inventory shifts in the prior year. Cereal and granola volume losses were primarily driven by category declines. Segment profit was $134.1 million, a decrease of 3.9%, or $5.5 million, compared to the prior year period. Segment Adjusted EBITDA (non-GAAP)* was $200.2 million, a decrease of 1.8%, or $3.6 million, compared to the prior year period.

For the six months ended March 31, 2026, net sales were $2,148.7 million, an increase of 10.1%, or $196.9 million, compared to the prior year period. Segment profit was $266.3 million, a decrease of 1.6%, or $4.3 million, compared to the prior year period. Segment Adjusted EBITDA was $403.5 million, a decrease of 1.2%, or $5.1 million, compared to the prior year period.

Foodservice

Primarily egg and potato products.

For the second quarter, net sales were $627.4 million, an increase of 3.2%, or $19.5 million, compared to the prior year period. Net sales included $6.5 million in the second quarter attributable to PPI. Excluding the benefit of PPI in the current year period, volumes increased 6.7%, driven by improved customer service levels and improved production in protein-based shakes. Segment profit was $109.8 million, an increase of 78.5%, or $48.3 million, compared to the prior year period. Segment Adjusted EBITDA was $142.0 million, an increase of 47.9%, or $46.0 million, compared to the prior year period.

For the six months ended March 31, 2026, net sales were $1,296.5 million, an increase of 5.9%, or $72.0 million, compared to the prior year period. Segment profit was $227.3 million, an increase of 54.0%, or $79.7 million, compared to the prior year period. Segment Adjusted EBITDA was $294.4 million, an increase of 38.3%, or $81.6 million, compared to the prior year period.

Refrigerated Retail

Primarily side dish, egg, cheese and sausage products.

For the second quarter, net sales were $235.3 million, an increase of 4.8%, or $10.7 million, compared to the prior year period. Volumes increased 5.6%, primarily due to an increase in side dish products driven by the introduction of private label offerings and the shifting of Easter demand into the quarter. Volume information by product is disclosed in a table presented later in this release. Segment profit was $22.1 million, an increase of 36.4%, or $5.9 million, compared to the prior year period. Segment Adjusted EBITDA was $40.8 million, an increase of 17.6%, or $6.1 million, compared to the prior year period.

For the six months ended March 31, 2026, net sales were $501.9 million, an increase of 2.2%, or $10.7 million, compared to the prior year period. Segment profit was $52.5 million, an increase of 30.0%, or $12.1 million, compared to the prior year period. Segment Adjusted EBITDA was $90.9 million, an increase of 19.1%, or $14.6 million, compared to the prior year period.

Weetabix

Primarily United Kingdom RTE cereal, muesli and protein-based shakes.

For the second quarter, net sales were $136.1 million, an increase of 3.3%, or $4.4 million, compared to the prior year period. Net sales reflected a foreign currency exchange rate tailwind of approximately 680 basis points. Volumes decreased 2.6%, primarily driven by product discontinuations and declines in private label products, partially offset by growth in protein-based shakes. Segment profit was $20.8 million, an increase of 14.3%, or $2.6 million, compared to the prior year period. Segment Adjusted EBITDA was $32.3 million, an increase of 6.6%, or $2.0 million, compared to the prior year period.

For the six months ended March 31, 2026, net sales were $274.0 million, an increase of 5.7%, or $14.7 million, compared to the prior year period. Segment profit was $42.5 million, an increase of 24.6%, or $8.4 million, compared to the prior year period. Segment Adjusted EBITDA was $65.4 million, an increase of 12.2%, or $7.1 million, compared to the prior year period.

Interest, Loss on Extinguishment of Debt, (Income) Expense on Swaps and Income Tax

Interest expense, net was $105.7 million and $209.1 million in the three and six months ended March 31, 2026, respectively, compared to $87.0 million and $171.1 million in the three and six months ended March 31, 2025, respectively. The increase in interest expense, net in the current year periods was driven by higher average outstanding principal amounts of debt, a higher weighted-average interest rate and lower interest income compared to the prior year periods.

There was no gain or loss on extinguishment of debt in the second quarter of fiscal year 2026 or 2025. Loss on extinguishment of debt, net of $17.5 million was recorded in the six months ended March 31, 2026 in connection with Post's redemption of its 5.50% senior notes due December 2029. Loss on extinguishment of debt, net of $5.8 million was recorded in the six months ended March 31, 2025 in connection with Post's redemption of its 5.625% senior notes due January 2028.

(Income) expense on swaps, net relates to mark-to-market adjustments and settlements on interest rate swaps. Income on swaps, net was $1.7 million in the second quarter of fiscal year 2026 compared to an expense of $5.5 million in the prior year period. Income on swaps, net was $3.6 million in the six months ended March 31, 2026 compared to $9.9 million in the prior year period.

Income tax expense was $28.1 million in the second quarter of fiscal year 2026, an effective income tax rate of 25.6%, compared to $20.0 million in the second quarter of fiscal year 2025, an effective income tax rate of 24.3%. Income tax expense was $55.4 million in the six months ended March 31, 2026, an effective income tax rate of 23.7%, compared to $52.1 million in the prior year period, an effective income tax rate of 22.9%.

Share Repurchases and New Share Repurchase Authorization

During the second quarter of fiscal year 2026, Post repurchased 3.3 million shares of its common stock for $331.0 million at an average price of $99.85 per share. During the six months ended March 31, 2026, Post repurchased 7.0 million shares for $709.9 million at an average price of $100.76. Subsequent to the end of the second quarter of fiscal year 2026 through May 5, 2026, Post repurchased 1.1 million shares for $111.9 million at an average price of $101.84 per share. On May 5, 2026, Post's Board of Directors approved a new $600 million share repurchase authorization. Shares repurchased under the new authorization may begin on May 9, 2026. As of May 5, 2026, Post had $236.6 million remaining under its existing $500 million share repurchase authorization, which became effective on February 7, 2026 and will be cancelled effective May 8, 2026.

Repurchases may be made from time to time in the open market, in private purchases, through forward, derivative, accelerated repurchase or automatic purchase transactions, or otherwise. Any shares repurchased would be held as treasury stock. The authorization does not, however, obligate Post to acquire any particular number of shares, and repurchases may be suspended or terminated at any time at Post's discretion.

Outlook

Post management affirmed its guidance range for fiscal year 2026 Adjusted EBITDA of $1,550-$1,580 million.

Post management expects fiscal year 2026 capital expenditures to range between $350-$390 million, which includes continued Foodservice investment in cage-free egg facility expansion and the completion of the Norwalk, Iowa precooked egg facility expansion for aggregate expenditures of $80-$90 million.

Post provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted EBITDA non-GAAP guidance measure to the most directly comparable GAAP measure due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for income/expense on swaps, net, integration and transaction costs, mark-to-market adjustments on equity security investments, mark-to-market adjustments on commodity and foreign exchange hedges, gain/loss on extinguishment of debt, net, equity method investment adjustment and other items reflected in Post's reconciliations of historical numbers, the amounts of which, based on historical experience, could be significant. For additional information regarding Post's non-GAAP measures, see the related explanations presented under "Use of Non-GAAP Measures."

Use of Non-GAAP Measures

Post uses certain non-GAAP measures in this release to supplement the financial measures prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP"). These non-GAAP measures include Adjusted net earnings/loss, Adjusted diluted earnings/loss per common share, Adjusted EBITDA, segment Adjusted EBITDA, Adjusted EBITDA as a percentage of Net Sales, segment Adjusted EBITDA as a percentage of Net Sales, free cash flow, net leverage as calculated under Post's credit agreement and consolidated interest coverage ratio as calculated under Post's credit agreement. The reconciliation of each of these non-GAAP measures to the most directly comparable GAAP measure is provided later in this release under "Explanation and Reconciliation of Non-GAAP Measures."

Management uses certain of these non-GAAP measures, including Adjusted EBITDA and segment Adjusted EBITDA, as key metrics in the evaluation of underlying company and segment performance, in making financial, operating and planning decisions and, in part, in the determination of bonuses for its executive officers and employees. Additionally, Post is required to comply with certain covenants and limitations that are based on variations of EBITDA in its financing documents. Management believes the use of these non-GAAP measures provides increased transparency and assists investors in understanding the underlying operating performance of Post and its segments and in the analysis of ongoing operating trends. Non-GAAP measures are not prepared in accordance with GAAP, as they exclude certain items as described later in this release. These non-GAAP measures may not be comparable to similarly titled measures of other companies. For additional information regarding Post's non-GAAP measures, see the related explanations provided under "Explanation and Reconciliation of Non-GAAP Measures."

Conference Call to Discuss Earnings Results and Outlook

Shortly following this release, Post will publish prepared remarks related to this release in the Investors section of its website (www.postholdings.com) under the Investor Events & Presentations and the Quarterly Results sections. Post will host a conference call on Friday, May 8, 2026 at 9:00 a.m. ET to respond to questions. Robert V. Vitale, Chairman, President and Chief Executive Officer, Nicolas Catoggio, Chief Operating Officer, and Matthew J. Mainer, Chief Financial Officer and Treasurer, will participate in the call.

Interested parties may join the conference call by dialing (800) 579-2543 in the United States and (785) 424-1789 from outside of the United States. The conference identification number is POSTQ226. Interested parties are invited to listen to the webcast of the conference call, which can be accessed by visiting the Investors section of Post's website.

A replay of the conference call will be available through Friday, May 15, 2026 by dialing (800) 839-4906 in the United States and (402) 220-2684 from outside of the United States. A webcast replay also will be available for a limited period on Post's website in the Investors section.

Prospective Financial Information

Prospective financial information is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the prospective financial information described above will not materialize or will vary significantly from actual results. For further discussion of some of the factors that may cause actual results to vary materially from the prospective financial information provided in this release, see "Forward-Looking Statements" below. Accordingly, the prospective financial information provided in this release is only an estimate of what Post's management believes is realizable as of the date of this release. It also should be recognized that the reliability of any forecasted financial data diminishes the further in the future that the data is forecasted. In light of the foregoing, the information should be viewed in context and undue reliance should not be placed upon it.

Forward-Looking Statements

Certain matters discussed in this release, in the prepared remarks published on Post's website and on Post's conference call are forward-looking statements, including Post's Adjusted EBITDA outlook for fiscal year 2026 and Post's capital expenditure outlook for fiscal year 2026. These forward-looking statements are sometimes identified from the use of forward-looking words such as "believe," "should," "could," "potential," "continue," "expect," "project," "estimate," "predict," "anticipate," "aim," "intend," "plan," "forecast," "target," "is likely," "will," "can," "may" or "would" or the negative of these terms or similar expressions, and include all statements regarding future performance, earnings projections, events or developments. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. These risks and uncertainties include, but are not limited to, the following:

volatility in the cost or availability of inputs to Post's businesses (including raw materials, energy and other supplies and freight); disruptions or inefficiencies in Post's supply chain, tariffs, inflation, highly pathogenic avian influenza and other agricultural diseases and pests, labor shortages, public health crises, weather events and fires and other events beyond Post's control; changes in economic conditions, financial instability, disruptions in capital and credit markets, changes in interest rates and fluctuations in foreign currency exchange rates; Post's and its customers' ability to compete in their respective product categories, including the success of pricing, advertising and promotional programs, declines in demand for Post's products and the ability to anticipate and respond to changes in consumer and customer preferences and behaviors; Post's ability to hire and retain talented personnel, increases in labor-related costs, employee safety, labor strikes, work stoppages, unionization efforts and other labor disruptions; Post's high leverage, its ability to obtain additional financing and service its outstanding debt (including covenants restricting the operation of its businesses) and a potential downgrade in Post's credit ratings; Post's ability to successfully implement business strategies to reduce costs or optimize its network; allegations that Post's products cause injury or illness, product recalls and withdrawals, product liability claims and other related litigation; the success of new product introductions; compliance with new, existing and changing laws and regulations; Post's reliance on third parties and others for the manufacture of many of its products; costs, business disruptions and reputational damage associated with information technology failures, cybersecurity incidents, information security breaches or enterprise resource planning system implementations; the impact of litigation; Post's ability to identify, complete and integrate or otherwise effectively execute acquisitions, including the pet food assets and operations acquired in April 2023 and December 2023 and 8th Avenue, or other strategic transactions; the loss of, a significant reduction of purchases by or the bankruptcy of a major customer; differences in Post's actual operating results from any of its guidance regarding its future performance; impairment in the carrying value of goodwill, other intangibles or long-lived assets or changes in critical accounting estimates; risks associated with Post's international businesses; business disruption or other losses resulting from changes in governmental administrations or regulatory priorities, political instability, terrorism, war or armed hostilities or geopolitical tensions; risks related to the intended tax treatment of Post's divestitures of its interest in BellRing Brands, Inc.; Post's ability to protect its intellectual property and other assets and to license third-party intellectual property; costs associated with the obligations of Bob Evans Farms, Inc. ("Bob Evans") in connection with the 2017 sale of its restaurants business, including certain indemnification obligations and Bob Evans's payment and performance obligations as a guarantor for certain leases; losses or increased funding and expenses related to Post's qualified pension or other postretirement plans; conflicting interests or the appearance of conflicting interests resulting from any of Post's directors or officers also serving as directors or officers of other companies; and other risks and uncertainties described in Post's filings with the Securities and Exchange Commission. These forward-looking statements represent Post's judgment as of the date of this release. Post disclaims, however, any intent or obligation to update these forward-looking statements.

About Post Holdings, Inc.

Post Holdings, Inc., headquartered in St. Louis, Missouri, is a consumer packaged goods holding company with businesses operating in the center-of-the-store, refrigerated, foodservice and food ingredient categories. Its businesses include Post Consumer Brands, Michael Foods, Bob Evans Farms and Weetabix. Post Consumer Brands is a leader in the North American branded and private label ready-to-eat cereal and granola, pet food and nut butter categories. Michael Foods and Bob Evans Farms are leaders in refrigerated foods, delivering innovative, value-added egg and refrigerated potato side dish products to the foodservice and retail channels. Weetabix is home to the United Kingdom's number one selling ready-to-eat cereal brand, Weetabix®. For more information, visit www.postholdings.com.

Contact:

Investor Relations
Daniel O'Rourke
[email protected]
(314) 806-3959

Media Relations
Tara Gray
[email protected]
(314) 644-7648

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in millions, except per share data)

Three Months Ended
March 31,

Six Months Ended

March 31,

2026

2025

2026

2025

Net Sales

$ 2,042.9

$ 1,952.1

$ 4,217.5

$ 3,926.8

Cost of goods sold

1,425.3

1,406.3

2,961.4

2,785.7

Gross Profit

617.6

545.8

1,256.1

1,141.1

Selling, general and administrative expenses

326.2

314.8

683.5

646.4

Amortization of intangible assets

51.0

49.1

102.7

98.2

Other operating expense (income), net

28.5

(0.3)

19.6

0.2

Operating Profit

211.9

182.2

450.3

396.3

Interest expense, net

105.7

87.0

209.1

171.1

Loss on extinguishment of debt, net

—

—

17.5

5.8

(Income) expense on swaps, net

(1.7)

5.5

(3.6)

(9.9)

Other (income) expense, net

(2.0)

7.3

(6.6)

1.5

Earnings before Income Taxes and Equity Method Earnings

109.9

82.4

233.9

227.8

Income tax expense

28.1

20.0

55.4

52.1

Equity method earnings, net of tax

(0.2)

(0.2)

(0.5)

(0.3)

Net Earnings Including Noncontrolling Interest

82.0

62.6

179.0

176.0

Less: Net earnings attributable to noncontrolling interest

0.1

—

0.3

0.1

Net Earnings

$      81.9

$      62.6

$    178.7

$    175.9

Earnings per Common Share:

Basic

$      1.71

$      1.11

$      3.59

$      3.07

Diluted

$      1.56

$      1.03

$      3.28

$      2.83

Weighted-Average Common Shares Outstanding:

Basic

47.9

56.4

49.8

57.3

Diluted

54.1

63.1

56.1

64.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(in millions)  

March 31, 2026

September 30, 2025

ASSETS

Current Assets

Cash and cash equivalents

$                269.4

$                176.7

Restricted cash

2.0

6.1

Receivables, net

728.8

735.4

Inventories

911.6

875.0

Current assets held for sale

21.1

116.3

Prepaid expenses and other current assets

118.9

115.4

Total Current Assets

2,051.8

2,024.9

Property, net

2,652.1

2,698.7

Goodwill

4,829.0

4,844.7

Other intangible assets, net

2,837.4

3,014.6

Other assets held for sale

60.3

424.8

Other assets

546.6

520.7

Total Assets

$           12,977.2

$           13,528.4

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities

Current portion of long-term debt

$                    1.3

$                    1.2

Accounts payable

618.3

624.0

Current liabilities held for sale

10.0

55.5

Other current liabilities

477.3

532.4

Total Current Liabilities

1,106.9

1,213.1

Long-term debt

7,629.1

7,421.7

Deferred income taxes

657.0

638.5

Other liabilities held for sale

11.7

119.7

Other liabilities

367.3

371.6

Total Liabilities

9,772.0

9,764.6

Shareholders' Equity

Common stock

0.9

0.9

Additional paid-in capital

5,376.9

5,370.7

Retained earnings

2,297.6

2,118.9

Accumulated other comprehensive (loss) income

(18.5)

8.7

Treasury stock, at cost

(4,462.6)

(3,746.1)

Total Shareholders' Equity Excluding Noncontrolling Interest

3,194.3

3,753.1

Noncontrolling interest

10.9

10.7

Total Shareholders' Equity

3,205.2

3,763.8

Total Liabilities and Shareholders' Equity

$           12,977.2

$           13,528.4

SELECTED CONDENSED CONSOLIDATED CASH FLOWS

INFORMATION (Unaudited)

(in millions)

Six Months Ended

March 31,

2026

2025

Cash provided by (used in):

Operating activities

$   478.0

$   471.1

Investing activities, including capital expenditures of $207.7 and $229.5

172.7

(342.2)

Financing activities

(561.6)

(292.7)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(0.5)

(1.8)

Net increase (decrease) in cash, cash equivalents and restricted cash

$     88.6

$  (165.6)

SEGMENT INFORMATION (Unaudited)

(in millions)

Three Months Ended
March 31,

Six Months Ended

March 31,

2026

2025

2026

2025

Net Sales

Post Consumer Brands

$ 1,044.9

$   987.9

$ 2,148.7

$ 1,951.8

Foodservice

627.4

607.9

1,296.5

1,224.5

Refrigerated Retail

235.3

224.6

501.9

491.2

Weetabix

136.1

131.7

274.0

259.3

Corporate and eliminations

(0.8)

—

(3.6)

—

Total

$ 2,042.9

$ 1,952.1

$ 4,217.5

$ 3,926.8

Segment Profit

Post Consumer Brands

$    134.1

$    139.6

$    266.3

$    270.6

Foodservice

109.8

61.5

227.3

147.6

Refrigerated Retail

22.1

16.2

52.5

40.4

Weetabix

20.8

18.2

42.5

34.1

SUPPLEMENTAL REFRIGERATED RETAIL SEGMENT INFORMATION (Unaudited)

The below table presents volume percentage changes for the current quarter compared to the prior year quarter for products within the Refrigerated Retail segment.

Product

Volume Percentage Change

All

5.6 %

Side dishes

12.4 %

Egg

2.0 %

Cheese

1.0 %

Sausage

1.1 %

EXPLANATION AND RECONCILIATION OF NON-GAAP MEASURES

Post uses certain non-GAAP measures in this release to supplement the financial measures prepared in accordance with U.S. GAAP. These non-GAAP measures include Adjusted net earnings/loss, Adjusted diluted earnings/loss per common share, Adjusted EBITDA, segment Adjusted EBITDA, Adjusted EBITDA as a percentage of Net Sales, segment Adjusted EBITDA as a percentage of Net Sales, free cash flow, net leverage as calculated under Post's credit agreement and consolidated interest coverage ratio as calculated under Post's credit agreement. The reconciliation of each of these non-GAAP measures to the most directly comparable GAAP measure is provided in the tables following this section. Non-GAAP measures are not prepared in accordance with GAAP, as they exclude certain items as described below. These non-GAAP measures may not be comparable to similarly titled measures of other companies.

Adjusted net earnings/loss and Adjusted diluted earnings/loss per common share
Post believes Adjusted net earnings/loss and Adjusted diluted earnings/loss per common share are useful to investors in evaluating Post's operating performance because they exclude items that affect the comparability of Post's financial results and could potentially distort an understanding of the trends in business performance.

Adjusted net earnings/loss and Adjusted diluted earnings/loss per common share are adjusted for the following items:

a.

Loss on amounts held for sale: Post has excluded losses recorded to adjust the carrying value of businesses, facilities and other assets and liabilities classified as held for sale as the amount and frequency of such adjustments are not consistent. Additionally, Post believes that these losses do not reflect expected ongoing future operating expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

b.

Restructuring and facility closure costs, including accelerated depreciation: Post has excluded certain costs associated with facility closures as the amount and frequency of such adjustments are not consistent. Additionally, Post believes that these costs do not reflect expected ongoing future operating expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

c.

Mark-to-market adjustments on commodity and foreign exchange hedges: Post has excluded the impact of mark-to-market adjustments on commodity and foreign exchange hedges due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates. Additionally, these adjustments are primarily non-cash items, and the amount and frequency of such adjustments are not consistent.

d.

Debt premiums paid/discounts received, net: Post has excluded payments and other expenses for premiums on debt extinguishment, net of gains realized on debt repurchased at a discount, as such payments are inconsistent in amount and frequency. Additionally, Post believes that these costs do not reflect expected ongoing future operating expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

e.

Integration costs and transaction costs: Post has excluded transaction costs related to professional service fees and other related costs associated with signed and closed business combinations and divestitures and integration costs incurred to integrate acquired or to-be-acquired businesses or assets as Post believes that these exclusions allow for more meaningful evaluation of Post's current operating performance and comparisons of Post's operating performance to other periods. Post believes such costs are generally not relevant to assessing or estimating the long-term performance of acquired businesses or assets as part of Post or the performance of the divested businesses or assets, and such costs are not factored into management's evaluation of potential acquisitions or Post's performance after completion of an acquisition or the evaluation to divest a business or asset. In addition, the frequency and amount of such charges varies significantly based on the size and timing of the transaction and the maturity of any businesses being acquired or divested. Also, the size, complexity and/or volume of past transactions, which often drive the magnitude of such expenses, may not be indicative of the size, complexity and/or volume of future transactions. By excluding these expenses, management is better able to evaluate Post's ability to utilize its existing assets and estimate the long-term value that acquired businesses or assets will generate for Post.

f.

Mark-to-market adjustments on equity security investments: Post has excluded the impact of mark-to-market adjustments on equity security investments due to the inherent volatility associated with such amounts based on changes in market pricing variations and as the amount and frequency of such adjustments are not consistent. Additionally, these adjustments are primarily non-cash items and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

g.

Income/expense on swaps, net: Post has excluded the impact of mark-to-market adjustments and cash settlements on interest rate swaps due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to estimates of fair value and economic conditions and as the amount and frequency of such adjustments are not consistent.

h.

Gain/loss on sale of business: Post has excluded gains and losses recorded on divestitures as the amount and frequency of such adjustments are not consistent. Additionally, Post believes that these gains and losses do not reflect expected ongoing future operating income and expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

i.

Asset disposal costs: Post has excluded costs recorded in connection with the disposal of certain assets which were never put into use and/or the demolition and site remediation of unused facilities as the amount and frequency of these costs are not consistent. Additionally, Post believes that these costs do not reflect expected ongoing future operating expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

j.

Costs expected to be indemnified, net: Post has excluded certain costs incurred and expected to be indemnified in connection with damaged assets and gains related to indemnification proceeds received above the carrying value of damaged assets as Post believes such gains and losses do not reflect expected ongoing future operating income and expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

k.

Provision for legal settlements: Post has excluded gains and losses recorded to recognize the anticipated or actual resolution of certain litigation as Post believes such gains and losses do not reflect expected ongoing future operating income and expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

l.

Advisory income: Post has excluded advisory income received from 8th Avenue prior to Post's acquisition of 8th Avenue as Post believes such income did not contribute to a meaningful evaluation of Post's operating performance or comparisons of Post's operating performance to other periods.

m.

Income tax effect on adjustments: Post has included the income tax impact of the non-GAAP adjustments using a rate described in the applicable footnote of the reconciliation tables to be consistent with the treatment of these adjustments in the calculation of the non-GAAP measure.

Adjusted EBITDA, segment Adjusted EBITDA, Adjusted EBITDA as a percentage of Net Sales and segment Adjusted EBITDA as a percentage of Net Sales
Post believes that Adjusted EBITDA is useful to investors in evaluating Post's operating performance and liquidity because (i) Post believes it is widely used to measure a company's operating performance without regard to items such as depreciation and amortization, which can vary depending upon accounting methods and the book value of assets, (ii) it presents a measure of corporate performance exclusive of Post's capital structure and the method by which the assets were acquired and (iii) it is a financial indicator of a company's ability to service its debt, as Post is required to comply with certain covenants and limitations that are based on variations of EBITDA in its financing documents. Post believes that segment Adjusted EBITDA is useful to investors in evaluating Post's operating performance because it allows for assessment of the operating performance of each reportable segment. Management uses Adjusted EBITDA to provide forward-looking guidance and uses Adjusted EBITDA and segment Adjusted EBITDA to forecast future results. Post believes that Adjusted EBITDA as a percentage of Net Sales and segment Adjusted EBITDA as a percentage of Net Sales are measures useful to investors in evaluating Post's operating performance because they allow for meaningful comparison of operating performance across periods.

Adjusted EBITDA and segment Adjusted EBITDA reflect adjustments for interest expense, net, income tax expense/benefit, and depreciation and amortization, and the following adjustments discussed above: loss on amounts held for sale, restructuring and facility closure costs, mark-to-market adjustments on commodity and foreign exchange hedges, integration costs and transaction costs, mark-to-market adjustments on equity security investments, income/expense on swaps, net, gain/loss on sale of business, asset disposal costs, costs expected to be indemnified, net, provision for legal settlements and advisory income. Additionally, Adjusted EBITDA and segment Adjusted EBITDA reflect adjustments for the following items:

n.

Stock-based compensation: Post's compensation strategy includes the use of stock-based compensation to attract and retain executives and employees by aligning their long-term compensation interests with shareholders' investment interests. Post has excluded stock-based compensation as stock-based compensation can vary significantly based on reasons such as the timing, size and nature of the awards granted and subjective assumptions which are unrelated to operational decisions and performance in any particular period and does not contribute to meaningful comparisons of Post's operating performances to other periods.

o.

Gain/loss on extinguishment of debt, net: Post has excluded gains and losses recorded on extinguishment of debt, inclusive of payments for premiums and tender fees and the write-off of debt issuance costs, net of gains realized on the write-off of unamortized debt premiums and debt repurchased at a discount, as such gains and losses are inconsistent in amount and frequency. Additionally, Post believes that these gains and losses do not reflect expected ongoing future operating income and expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

p.

Equity method investment adjustment: Post has included adjustments for its portion of income tax expense/benefit, interest expense, net and depreciation and amortization for Weetabix's unconsolidated investment accounted for using equity method accounting as Post believes these adjustments contribute to a more meaningful evaluation of Post's current operating performance.

q.

Noncontrolling interest adjustment: Post has included adjustments for income tax expense/benefit, interest expense, net and depreciation and amortization for Weetabix's consolidated investment which is attributable to the noncontrolling owners of Weetabix's consolidated investment as Post believes these adjustments contribute to a more meaningful evaluation of Post's current operating performance.

Free cash flow
Free cash flow is a non-GAAP measure which represents net cash provided by operating activities less capital expenditures. Post believes free cash flow is useful to investors in evaluating Post's ability to service debt and repurchase shares of its common stock.

Net leverage as calculated under Post's credit agreement
Net leverage as calculated under Post's credit agreement is a non-GAAP measure which represents principal debt less cash and cash equivalents divided by Adjusted EBITDA for the last twelve months adjusted for certain items as provided in Post's credit agreement. Post believes this measure is useful to investors in determining Post's debt levels and ability to service debt. Adjusted EBITDA for the last twelve months reflects the adjustments for Adjusted EBITDA and segment Adjusted EBITDA discussed within the Adjusted EBITDA, segment Adjusted EBITDA, Adjusted EBITDA as a percentage of Net Sales and segment Adjusted EBITDA as a percentage of Net Sales section above, as well as adjustments for the following items (which were relevant for the year ended September 30, 2025):

r.

Impairment of goodwill: Post has excluded expenses for impairment of the Cheese and Dairy reporting unit as such non-cash amounts are inconsistent in amount and frequency and Post believes that these costs do not reflect expected ongoing future operating expenses and do not contribute to a meaningful evaluation of Post's current operating performance or comparisons of Post's operating performance to other periods.

s.

Inventory revaluation adjustment on acquired businesses: Post has excluded the impact of fair value step-up adjustments to inventory in connection with business combinations as such adjustments represent non-cash items, are not consistent in amount and frequency and are significantly impacted by the timing and size of Post's acquisitions.

Consolidated interest coverage ratio as calculated under Post's credit agreement
Consolidated interest coverage ratio as calculated under Post's credit agreement is a non-GAAP measure which represents Adjusted EBITDA for the last twelve months adjusted for certain items as provided in Post's credit agreement (which reflects the adjustments for Adjusted EBITDA discussed under the Net leverage as calculated under Post's credit agreement section above) divided by interest expense, net for the last twelve months. Post believes this measure is useful to investors in determining Post's ability to service debt.

RECONCILIATION OF NET EARNINGS TO ADJUSTED NET EARNINGS (Unaudited)

(in millions)

Three Months Ended
March 31,

Six Months Ended

March 31,

2026

2025

2026

2025

Net Earnings

$     81.9

$     62.6

$   178.7

$   175.9

Adjustments:

Loss on amounts held for sale

28.3

—

28.3

—

Restructuring and facility closure costs, including accelerated
depreciation

13.4

11.0

36.4

14.6

Mark-to-market adjustments on commodity and foreign exchange
hedges

(17.6)

2.3

(17.4)

(4.4)

Debt premiums paid

—

—

22.6

4.4

Integration costs

3.3

5.1

7.6

20.7

Mark-to-market adjustments on equity security investments

0.5

9.9

(1.7)

6.6

(Income) expense on swaps, net

(1.7)

5.5

(3.6)

(9.9)

Gain on sale of business

—

—

(9.7)

—

Asset disposal costs

3.6

0.2

5.2

0.4

Transaction costs

1.9

0.4

2.4

1.0

Costs expected to be indemnified, net

(1.4)

—

(1.0)

—

Provision for legal settlements

—

0.1

0.1

0.1

Advisory income

—

(0.1)

—

(0.3)

Total Net Adjustments

30.3

34.4

69.2

33.2

Income tax effect on adjustments (1)

(7.5)

(8.3)

(19.4)

(8.4)

Adjusted Net Earnings

$   104.7

$     88.7

$   228.5

$   200.7

(1) Income tax effect on adjustments was calculated on all items, except income/expense on swaps, net and gain/loss on sale of business, using a rate of 24.5%, the sum of Post's U.S. federal corporate income tax rate plus Post's blended state income tax rate, net of federal income tax benefit. Income tax effect for income/expense on swaps, net was calculated using a rate of 21.5%. Income tax effect for gain/loss on sale of business was calculated using a rate of 0.0%.

RECONCILIATION OF DILUTED EARNINGS PER COMMON SHARE

TO ADJUSTED DILUTED EARNINGS PER COMMON SHARE (Unaudited)

Three Months Ended
March 31,

Six Months Ended

March 31,

2026

2025

2026

2025

Diluted Earnings per Common Share

$     1.56

$     1.03

$     3.28

$     2.83

Adjustment to Diluted Earnings per Common Share for impact of
interest expense, net of tax, related to convertible senior notes (1)

(0.05)

(0.04)

(0.10)

(0.08)

Adjustments:

Loss on amounts held for sale

0.52

—

0.50

—

Restructuring and facility closure costs, including accelerated
depreciation

0.25

0.17

0.65

0.23

Mark-to-market adjustments on commodity and foreign exchange
hedges

(0.33)

0.04

(0.31)

(0.07)

Debt premiums paid

—

—

0.40

0.07

Integration costs

0.06

0.08

0.14

0.32

Mark-to-market adjustments on equity security investments

0.01

0.16

(0.03)

0.10

(Income) expense on swaps, net

(0.03)

0.09

(0.06)

(0.16)

Gain on sale of business

—

—

(0.17)

—

Asset disposal costs

0.07

—

0.09

—

Transaction costs

0.04

0.01

0.04

0.02

Costs expected to be indemnified, net

(0.02)

—

(0.01)

—

Total Net Adjustments

0.57

0.55

1.24

0.51

Income tax effect on adjustments (2)

(0.14)

(0.13)

(0.35)

(0.13)

Adjusted Diluted Earnings per Common Share

$     1.94

$     1.41

$     4.07

$     3.13

(1) Represents the exclusion of interest expense, net of tax, associated with Post's convertible senior notes, which was treated as an adjustment to income available to common shareholders for diluted earnings per common share. Post believes this exclusion allows for more meaningful comparison of performance to other periods.

(2) Income tax effect on adjustments was calculated on all items, except income/expense on swaps, net and gain/loss on sale of business, using a rate of 24.5%, the sum of Post's U.S. federal corporate income tax rate plus Post's blended state income tax rate, net of federal income tax benefit. Income tax effect for income/expense on swaps, net was calculated using a rate of 21.5%. Income tax effect for gain/loss on sale of business was calculated using a rate of 0.0%.

RECONCILIATION OF NET EARNINGS TO ADJUSTED EBITDA (Unaudited)

($ in millions)

Three Months Ended
March 31,

Six Months Ended

March 31,

2026

2025

2026

2025

Net Earnings

$   81.9

$   62.6

$ 178.7

$ 175.9

Interest expense, net

105.7

87.0

209.1

171.1

Income tax expense

28.1

20.0

55.4

52.1

Depreciation and amortization

138.2

125.6

290.7

245.9

Stock-based compensation

19.5

20.3

41.9

40.1

Loss on amounts held for sale

28.3

—

28.3

—

Loss on extinguishment of debt, net

—

—

17.5

5.8

Restructuring and facility closure costs, excluding accelerated
depreciation

4.7

7.6

9.7

11.2

Mark-to-market adjustments on commodity and foreign exchange
hedges

(17.6)

2.3

(17.4)

(4.4)

Integration costs

3.3

5.1

7.6

20.7

Mark-to-market adjustments on equity security investments

0.5

9.9

(1.7)

6.6

(Income) expense on swaps, net

(1.7)

5.5

(3.6)

(9.9)

Gain on sale of business

—

—

(9.7)

—

Asset disposal costs

3.6

0.2

5.2

0.4

Transaction costs

1.9

0.4

2.4

1.0

Costs expected to be indemnified, net

(1.4)

—

(1.0)

—

Provision for legal settlements

—

0.1

0.1

0.1

Advisory income

—

(0.1)

—

(0.3)

Equity method investment adjustment

0.1

0.1

0.2

0.2

Noncontrolling interest adjustment

(0.1)

(0.1)

(0.2)

(0.1)

Adjusted EBITDA

$ 395.0

$ 346.5

$ 813.2

$ 716.4

Net Earnings as a percentage of Net Sales

4.0 %

3.2 %

4.2 %

4.5 %

Adjusted EBITDA as a percentage of Net Sales

19.3 %

17.8 %

19.3 %

18.2 %

RECONCILIATION OF SEGMENT PROFIT TO ADJUSTED EBITDA (Unaudited)

THREE MONTHS ENDED MARCH 31, 2026

($ in millions)

Post
Consumer
Brands

Foodservice

Refrigerated
Retail

Weetabix

Corporate/
Other

Segment Profit

$  134.1

$  109.8

$    22.1

$    20.8

$        —

General corporate expenses and other

—

—

—

—

(72.9)

Other income, net

—

—

—

—

(2.0)

Operating Profit

134.1

109.8

22.1

20.8

(74.9)

Other income, net

—

—

—

—

2.0

Depreciation and amortization

63.1

35.5

18.4

11.5

9.7

Stock-based compensation

—

—

—

—

19.5

Loss on amounts held for sale

—

—

—

—

28.3

Restructuring and facility closure costs, excluding
accelerated depreciation

—

—

—

—

4.7

Mark-to-market adjustments on commodity and foreign
exchange hedges

—

(1.9)

—

(0.1)

(15.6)

Integration costs

3.0

—

0.3

—

—

Mark-to-market adjustments on equity security
investments

—

—

—

—

0.5

Asset disposal costs

—

—

—

—

3.6

Transaction costs

—

—

—

—

1.9

Costs expected to be indemnified, net

—

(1.4)

—

—

—

Equity method investment adjustment

—

—

—

0.3

—

Noncontrolling interest adjustment

—

—

—

(0.2)

—

Adjusted EBITDA

$  200.2

$  142.0

$    40.8

$    32.3

$     (20.3)

Segment Profit as a percentage of Net Sales

12.8 %

17.5 %

9.4 %

15.3 %

—

Adjusted EBITDA as a percentage of Net Sales

19.2 %

22.6 %

17.3 %

23.7 %

—

RECONCILIATION OF SEGMENT PROFIT TO ADJUSTED EBITDA (Unaudited)

THREE MONTHS ENDED MARCH 31, 2025

($ in millions)

Post
Consumer
Brands

Foodservice

Refrigerated
Retail

Weetabix

Corporate/
Other

Segment Profit

$  139.6

$    61.5

$    16.2

$    18.2

$        —

General corporate expenses and other

—

—

—

—

(60.6)

Other expense, net

—

—

—

—

7.3

Operating Profit

139.6

61.5

16.2

18.2

(53.3)

Other expense, net

—

—

—

—

(7.3)

Depreciation and amortization

59.4

32.1

18.1

11.8

4.2

Stock-based compensation

—

—

—

—

20.3

Restructuring and facility closure costs, excluding
accelerated depreciation

—

—

—

—

7.6

Mark-to-market adjustments on commodity and foreign
exchange hedges

—

2.4

—

0.1

(0.2)

Integration costs

4.8

—

0.3

—

—

Mark-to-market adjustments on equity security
investments

—

—

—

—

9.9

Asset disposal costs

—

—

—

—

0.2

Transaction costs

—

—

—

—

0.4

Provision for legal settlements

—

—

0.1

—

—

Advisory income

—

—

—

—

(0.1)

Equity method investment adjustment

—

—

—

0.3

—

Noncontrolling interest adjustment

—

—

—

(0.1)

—

Adjusted EBITDA

$  203.8

$    96.0

$    34.7

$    30.3

$     (18.3)

Segment Profit as a percentage of Net Sales

14.1 %

10.1 %

7.2 %

13.8 %

—

Adjusted EBITDA as a percentage of Net Sales

20.6 %

15.8 %

15.4 %

23.0 %

—

RECONCILIATION OF SEGMENT PROFIT TO ADJUSTED EBITDA (Unaudited)

SIX MONTHS ENDED MARCH 31, 2026

($ in millions)

Post
Consumer
Brands

Foodservice

Refrigerated
Retail

Weetabix

Corporate/
Other

Segment Profit

$  266.3

$  227.3

$    52.5

$    42.5

$        —

General corporate expenses and other

—

—

—

—

(131.7)

Other income, net

—

—

—

—

(6.6)

Operating Profit

266.3

227.3

52.5

42.5

(138.3)

Other income, net

—

—

—

—

6.6

Depreciation and amortization

130.2

71.3

37.7

22.8

28.7

Stock-based compensation

—

—

—

—

41.9

Loss on amounts held for sale

—

—

—

—

28.3

Restructuring and facility closure costs, excluding
accelerated depreciation

—

—

—

—

9.7

Mark-to-market adjustments on commodity and foreign
exchange hedges

—

(3.2)

—

(0.1)

(14.1)

Integration costs

6.9

—

0.7

—

—

Mark-to-market adjustments on equity security
investments

—

—

—

—

(1.7)

Gain on sale of business

—

—

—

—

(9.7)

Asset disposal costs

—

—

—

—

5.2

Transaction costs

—

—

—

—

2.4

Costs expected to be indemnified, net

—

(1.0)

—

—

—

Provision for legal settlements

0.1

—

—

—

—

Equity method investment adjustment

—

—

—

0.7

—

Noncontrolling interest adjustment

—

—

—

(0.5)

—

Adjusted EBITDA

$  403.5

$  294.4

$    90.9

$    65.4

$     (41.0)

Segment Profit as a percentage of Net Sales

12.4 %

17.5 %

10.5 %

15.5 %

—

Adjusted EBITDA as a percentage of Net Sales

18.8 %

22.7 %

18.1 %

23.9 %

—

RECONCILIATION OF SEGMENT PROFIT TO ADJUSTED EBITDA (Unaudited)

SIX MONTHS ENDED MARCH 31, 2025

($ in millions)

Post
Consumer
Brands

Foodservice

Refrigerated
Retail

Weetabix

Corporate/
Other

Segment Profit

$  270.6

$  147.6

$    40.4

$    34.1

$         —

General corporate expenses and other

—

—

—

—

(97.9)

Other expense, net

—

—

—

—

1.5

Operating Profit

270.6

147.6

40.4

34.1

(96.4)

Other expense, net

—

—

—

—

(1.5)

Depreciation and amortization

117.6

63.8

35.5

23.8

5.2

Stock-based compensation

—

—

—

—

40.1

Restructuring and facility closure costs, excluding
accelerated depreciation

—

—

—

—

11.2

Mark-to-market adjustments on commodity and foreign
exchange hedges

—

1.4

—

0.1

(5.9)

Integration costs

20.4

—

0.3

—

—

Mark-to-market adjustments on equity security
investments

—

—

—

—

6.6

Asset disposal costs

—

—

—

—

0.4

Transaction costs

—

—

—

—

1.0

Provision for legal settlements

—

—

0.1

—

—

Advisory income

—

—

—

—

(0.3)

Equity method investment adjustment

—

—

—

0.5

—

Noncontrolling interest adjustment

—

—

—

(0.2)

—

Adjusted EBITDA

$  408.6

$  212.8

$    76.3

$    58.3

$     (39.6)

Segment Profit as a percentage of Net Sales

13.9 %

12.1 %

8.2 %

13.2 %

—

Adjusted EBITDA as a percentage of Net Sales

20.9 %

17.4 %

15.5 %

22.5 %

—

RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW (Unaudited)

(in millions)

Six Months Ended

March 31,

2026

2025

Net cash provided by operating activities

$   478.0

$   471.1

Less: Capital expenditures

207.7

229.5

Free Cash Flow

$   270.3

$   241.6

RECONCILIATION OF NET EARNINGS TO NET LEVERAGE

AND CONSOLIDATED INTEREST COVERAGE RATIO (Unaudited)

($ in millions)

Year Ended

September 30,

Six Months Ended

March 31,

Twelve Months

Ended March 31,

2025

2026

2025

2026

Net Earnings

$            335.7

$   178.7

$   175.9

$            338.5

Interest expense, net

361.4

209.1

171.1

399.4

Income tax expense

108.7

55.4

52.1

112.0

Depreciation and amortization

524.3

290.7

245.9

569.1

Stock-based compensation

81.6

41.9

40.1

83.4

Loss on amounts held for sale

—

28.3

—

28.3

Loss on extinguishment of debt, net

5.8

17.5

5.8

17.5

Restructuring and facility closure costs, excluding accelerated
depreciation

23.4

9.7

11.2

21.9

Mark-to-market adjustments on commodity and foreign
exchange hedges

(5.0)

(17.4)

(4.4)

(18.0)

Integration costs

38.7

7.6

20.7

25.6

Mark-to-market adjustments on equity security investments

6.6

(1.7)

6.6

(1.7)

Income on swaps, net

(6.9)

(3.6)

(9.9)

(0.6)

Gain on sale of business

—

(9.7)

—

(9.7)

Asset disposal costs

6.3

5.2

0.4

11.1

Transaction costs

6.2

2.4

1.0

7.6

Costs expected to be indemnified, net

—

(1.0)

—

(1.0)

Provision for legal settlements

0.7

0.1

0.1

0.7

Advisory income

(0.5)

—

(0.3)

(0.2)

Equity method investment adjustment

0.4

0.2

0.2

0.4

Noncontrolling interest adjustment

(0.4)

(0.2)

(0.1)

(0.5)

Impairment of goodwill

29.8

—

—

29.8

Inventory revaluation adjustment on acquired businesses

22.0

—

—

22.0

Adjusted EBITDA

$          1,538.8

$   813.2

$   716.4

$          1,635.6

March 31, 2026

Long-term debt

$          7,629.1

Plus: Current portion of long-term debt

1.3

Debt issuance costs, net

58.7

Less: Unamortized premium, net

13.1

Total principal debt

7,676.0

Less: Cash and cash equivalents

269.4

Net Debt

$          7,406.6

Adjusted EBITDA for the twelve months ended March 31, 2026

$          1,635.6

Credit agreement adjustments to Adjusted EBITDA for the twelve months ended March 31, 2026

11.3

Adjusted EBITDA for the twelve months ended March 31, 2026 as calculated under Post's credit
agreement

$          1,646.9

Net leverage as calculated under Post's credit agreement

4.5x

Adjusted EBITDA for the twelve months ended March 31, 2026 as calculated under Post's credit
agreement

$          1,646.9

Interest expense, net for the twelve months ended March 31, 2026

399.4

Consolidated interest coverage ratio as calculated under Post's credit agreement

4.1x

SOURCE Post Holdings, Inc.

For the quarter ended March 2026, Post Holdings (POST - Free Report) reported revenue of $2.04 billion, up 4.7% over the same period last year. EPS came in at $1.94, compared to $1.41 in the year-ago quarter.

The reported revenue represents a surprise of -0.93% over the Zacks Consensus Estimate of $2.06 billion. With the consensus EPS estimate being $1.64, the EPS surprise was +18.29%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Post Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Weetabix: $136.1 million versus $141.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.3% change.Net Sales- Refrigerated Retail: $235.3 million versus the two-analyst average estimate of $229.02 million. The reported number represents a year-over-year change of +4.8%.Net Sales- Post Consumer Brands: $1.04 billion compared to the $1.06 billion average estimate based on two analysts. The reported number represents a change of +5.8% year over year.Net Sales- Eliminations: $-0.8 million versus $-1.63 million estimated by two analysts on average.Net Sales- Foodservice: $627.4 million versus the two-analyst average estimate of $632.77 million. The reported number represents a year-over-year change of +3.2%.Adjusted EBITDA- Post Consumer Brands: $200.2 million versus $191.82 million estimated by two analysts on average.Adjusted EBITDA- Weetabix: $32.3 million versus $34.02 million estimated by two analysts on average.Adjusted EBITDA- Foodservice: $142 million versus the two-analyst average estimate of $134.55 million.Adjusted EBITDA- Corporate/ Other: $-20.3 million versus the two-analyst average estimate of $-20 million.Adjusted EBITDA- Refrigerated Retail: $40.8 million compared to the $43 million average estimate based on two analysts.View all Key Company Metrics for Post Holdings here>>>

Shares of Post Holdings have returned +2.2% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Key Takeaways Post Holdings Q2 adjusted EPS rose 37.6% to $1.94, topping estimates despite a sales miss. POST Foodservice EBITDA surged 47.9% as volumes improved and shake production increased.Post Holdings kept FY26 EBITDA outlook of $1.55B-$1.58B and approved a $600M buyback. Post Holdings, Inc. (POST - Free Report) delivered second-quarter fiscal 2026 results, with both the top and bottom lines showing year-over-year growth. However, the top line missed the Zacks Consensus Estimate, while the bottom line surpassed.

POST’s Q2 Key Performance MetricsPOST’s adjusted earnings per share increased 37.6% to $1.94 from $1.41 in the prior-year period and surpassed the Zacks Consensus Estimate of $1.64.

Net sales increased 4.7% year over year to $2,042.9 million from $1,952.1 million in the prior-year period. The increase included a contribution of $152.3 million in net sales from acquisitions during the current-year period. The figure missed the Zacks Consensus Estimate of $2,062 million.

Post Holdings’ Margin & Cost PerformanceGross profit increased 13.2% year over year to $617.6 million from $545.8 million in the prior-year period. Gross margin also expanded to 30.2% from 28% in the prior-year period.

Selling, general and administrative expenses increased 3.6% year over year to $326.2 million. However, SG&A expenses as a percentage of net sales improved slightly to 16% from 16.1%, reflecting relatively stable expense leverage during the quarter.
Operating profit climbed 16.3% year over year to $211.9 million from $182.2 million in the prior-year period. Fiscal second-quarter operating profit included a $28.3 million loss on amounts held for sale related to Crystal Farms Dairy Company, which was treated as an adjustment for non-GAAP measures.

Post Holdings’ Segmental PerformancePost Consumer Brands’ net sales increased 5.8% year over year to $1,044.9 million. The Zacks Consensus Estimate is pegged at $1,059 million. Net sales included a $145 million contribution from 8th Avenue. Excluding 8th Avenue, volumes declined 10%, reflecting a 14.1% decline in pet food volumes and a 3.5% decline in cereal and granola volumes. Segment adjusted EBITDA declined 1.8% to $200.2 million, while beating the Zacks Consensus Estimate of $192 million.

Foodservice segment net sales increased 3.2% year over year to $627.4 million, missing the Zacks Consensus Estimate of $633 million. Net sales of Foodservice included a $6.5 million contribution from PPI. Excluding PPI, volumes increased 6.7%, driven by improved customer service levels and higher production in protein-based shakes. Segment adjusted EBITDA increased 47.9% to $142 million, which beat the Zacks Consensus Estimate of $135 million.

Net sales in the Refrigerated Retail segment increased 4.8% year over year to $235.3 million, supported by a 5.6% increase in volumes. This beat the Zacks Consensus Estimate of $229 million. Growth was primarily driven by higher side-dish product volumes following the introduction of private-label offerings and the shift of Easter demand into the quarter. Segment adjusted EBITDA rose 17.6% to $40.8 million, missing the Zacks Consensus Estimate of $43 million.

Weetabix net sales increased 3.3% year over year to $136.1 million, supported by a foreign currency exchange rate tailwind of approximately 680 basis points. The figure missed the Zacks Consensus Estimate of $141 million. Volumes declined 2.6%, primarily due to product discontinuations and weakness in private-label products, partially offset by growth in protein-based shakes. Segment adjusted EBITDA rose 6.6% to $32.3 million, but missed the Zacks Consensus Estimate of $34 million.

Post Capital Allocation & Financial Position.During the second quarter of fiscal 2026, Post Holdings repurchased 3.3 million shares for $331 million at an average price of $99.85 per share. During the first six months of fiscal 2026, the company repurchased 7 million shares for $709.9 million at an average price of $100.76. Following the quarter through May 5, 2026, POST repurchased an additional 1.1 million shares for $111.9 million. Management also approved a new $600 million share repurchase authorization effective May 9, 2026.

The company ended the quarter with cash and cash equivalents of $269.4 million and long-term debt of $7,629.1 million.

What to Expect From Post Holdings in the Future?Post Holdings maintained its full-year adjusted EBITDA guidance range of $1,550 million to $1,580 million while incorporating new cost pressures and uncertainty related to the conflict in the Middle East.

The company expects adjusted EBITDA performance in the remaining two quarters to slightly favor the fourth quarter, driven by seasonality within PCB cereal. Foodservice results are expected to align with the previously indicated $500 million annual run rate.

The company also maintained its full-year capital expenditure projection of $350 million to $390 million, with lower spending anticipated in the second half of the fiscal year.

This Zacks Rank #2 (Buy) company’s shares have gained 4% in the year-to-date period against the industry’s decline of 1.8%.

Image Source: Zacks Investment Research

Other Stocks to ConsiderSome ohter top-ranked stocks have been discussed below:

The Chef’s Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East, and Canada. CHEF currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 8.3 and 24.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 28.9%, on average.

Darling Ingredients Inc. (DAR - Free Report) develops, produces, and sells sustainable natural ingredients from edible and inedible bio-nutrients in North America, Europe, China, South America, and internationally. DAR currently carries a Zacks Rank #2.

The Zacks Consensus Estimate for DAR’s current fiscal-year sales and earnings implies growth of 7.1% and 567.7%, respectively, from the year-ago actuals. DAR delivered a trailing four-quarter negative earnings surprise of 16.1%, on average.

Ambev S.A. (ABEV - Free Report) engages in the production, distribution, and sale of beer, draft beer, soft drinks, malt and food, and other beverages. ABEV currently carries a Zacks Rank #2.

The Zacks Consensus Estimate for ABEV’s current fiscal-year sales and earnings indicates growth of 17.4% and 11.1%, respectively.

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company value investors might notice is Post Holdings (POST - Free Report) . POST is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 12.87. This compares to its industry's average Forward P/E of 13.65. Over the past year, POST's Forward P/E has been as high as 19.52 and as low as 12.72, with a median of 16.42.

We should also highlight that POST has a P/B ratio of 1.44. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 1.63. Over the past year, POST's P/B has been as high as 1.75 and as low as 1.42, with a median of 1.62.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. POST has a P/S ratio of 0.55. This compares to its industry's average P/S of 0.7.

Finally, investors should note that POST has a P/CF ratio of 7.45. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. POST's P/CF compares to its industry's average P/CF of 10.95. Within the past 12 months, POST's P/CF has been as high as 9.41 and as low as 7.35, with a median of 8.35.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Post Holdings is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, POST feels like a great value stock at the moment.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Post Holdings (POST - Free Report) Based in Missouri, Post Holdings is a consumer-packaged goods holding company, which is involved in the production of center-of-the-store, refrigerated, foodservice, food ingredient and convenient nutrition product categories. It also engages in the private brand food category. On Mar 10, 2022, the company concluded the distribution of 80.1% of its interest in BellRing Brands, Inc. to its shareholders.

POST is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. POST has a Growth Style Score of B, forecasting year-over-year earnings growth of 4.8% for the current fiscal year.

One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.29 to $7.58 per share. POST boasts an average earnings surprise of +19.3%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, POST should be on investors' short list.

Post Holdings is rated a "Buy," with shares offering ~20% upside to a ~$115 fair value target. POST's aggressive buyback program has reduced share count by 15% this year, supporting double-digit free cash flow yield. Foodservice and refrigerated retail units show strong growth, offsetting structural declines in cereal and pet food segments.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Post Holdings (POST - Free Report) Post Holdings, Inc. is a consumer-packaged goods holding company based in Missouri. The company operates across center-of-the-store, refrigerated, foodservice, food ingredient and convenient nutrition categories. It also participates in private brand food. In March 2022, Post Holdings completed the distribution of 80.1% of its interest in BellRing Brands, Inc. to its shareholders.

POST is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. POST has a Growth Style Score of B, forecasting year-over-year earnings growth of 4.8% for the current fiscal year.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.34 to $7.58 per share. POST boasts an average earnings surprise of +19.3%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, POST should be on investors' short list.

The company's revenue rose 10% to $1.20 billion, bolstered by strength at its lingerie brand Aerie.

Abercrombie Rallies as Strong Q1 Earnings Extend Winning StreakAmerican Eagle Outfitters NYSE: AEO reported first-quarter revenue growth and operating income ahead of its guidance, as continued momentum at Aerie and OFFLINE offset weaker trends in parts of the namesake American Eagle brand.

Executive Chairman and Chief Executive Officer Jay Schottenstein said the quarter “reflected the strength of our portfolio, the power of Aerie, and work underway at American Eagle.” The company reported revenue of $1.2 billion, up 10% from last year, with operating income of $28 million. Comparable sales increased 8%.

Get AEO alerts:

5 Retail Stocks That Could Deck the Halls—or Wreck PortfoliosSchottenstein said Aerie surpassed $2 billion in revenue on a trailing 12-month basis, while American Eagle saw strength in men’s and tops but weakness in women’s bottoms, including denim. “We are pleased with performance of the quarter,” Schottenstein said, while adding that the company has “identified specific opportunities to better position women’s bottoms.”

Aerie and OFFLINE Drive Growth Aerie and OFFLINE continued to be the strongest part of the portfolio. Schottenstein said the brands generated revenue of $481 million, up 34% from last year, supported by demand across categories and channels.

MarketBeat Week in Review – 07/28 - 08/01Jennifer Foyle, President and Executive Creative Director for American Eagle and Aerie, said Aerie is “firing on all cylinders,” pointing to broad-based category strength and a 45% comparable sales increase in Aerie apparel. She said Aerie’s head-to-toe merchandising strategy across intimates, sleep and apparel is helping simplify outfitting for customers while increasing basket size and average order value.

Foyle said intimates delivered high single-digit comparable sales growth, led by a record performance in the undies business, and sleep continues to scale as a longer-term growth category. She also highlighted a shift away from brand-wide promotions toward more targeted promotions, always-on pricing in key categories and marketing focused on acquiring and retaining higher-value customers.

The company also cited marketing as a contributor to Aerie’s performance, including the 100% AerieREAL campaign featuring Pamela Anderson. Foyle said the campaign reinforces Aerie’s commitment to inclusivity and authenticity, including a promise not to use AI-generated bodies or people in marketing.

OFFLINE also continued to gain traction. Foyle said the activewear brand is seeing customer response to new silhouettes, styles and fabrications, including matching sets and curated color drops. She said OFFLINE is currently the No. 2 legging brand within the company’s core demographic and is “well on its way to becoming its own activewear brand.”

American Eagle Results Mixed as Women’s Bottoms Weigh The American Eagle brand posted weaker results, with total sales down 2% and comparable sales also down 2%. Chief Financial Officer Mike Mathias said American Eagle’s digital performance was flat, while the comparable sales decline was driven by stores.

Foyle said the American Eagle men’s business delivered its third consecutive quarter of positive growth, with gains across tops and bottoms. Women’s tees and fashion tops also performed well. However, women’s bottoms underperformed expectations and were the primary driver of the brand’s sales decline.

“We know what needs to be corrected, and the teams are aligned and activated to return AE to growth,” Foyle said.

She said the company needs to better distort into specific styles and fits, and that a colder spring hurt demand in seasonal categories. For the back-to-school period, Foyle said the company is refining its bottoms architecture, optimizing key silhouettes and rises, and using chase capabilities to add newness.

During the question-and-answer portion of the call, Foyle said the team has already tested for back-to-school and has identified working rises and fits. She said more recent results in denim have improved, though she did not provide specific figures. Schottenstein said he expects American Eagle to return to positive comparable sales growth in the back half of the year.

Margins Improve, Inventory and Tariffs in Focus Mathias said first-quarter gross profit increased 41% to $456 million, while gross margin expanded 860 basis points to 38.2%. Merchandise margin improved 710 basis points, primarily due to the comparison against last year’s inventory write-down. Buying, occupancy and warehousing expenses leveraged 150 basis points, aided by sales growth and initiatives to control delivery and distribution costs, including benefits from winding down third-party fulfillment operations.

SG&A expenses rose 11%, driven by planned advertising investments. Interest expense increased due to a transaction agreement under which the company sold a portion of its tariff claims, while other income increased due to an unrealized gain on investments. Depreciation was flat at $51 million. The company reported a first-quarter tax rate of approximately 17% and earnings per share of $0.14.

Ending inventory at cost was up 27%, while units were up 5%. Mathias said the difference reflected incremental tariffs this year and the comparison to last year’s inventory write-down. Normalizing for those factors, he said inventory cost dollars would have been up in the high single-digit range.

Tariffs remained a key topic on the call. Mathias said the company expects a $20 million incremental tariff headwind in the second quarter versus last year. The company is planning for a 10% tariff rate on imports in the second quarter and 15% for the balance of the year.

Mathias said American Eagle Outfitters has applied for roughly $190 million in tariff refunds and anticipates a $140 million net cash benefit, though that benefit is not included in guidance. He said the company has received more than $100 million back so far and has about $75 million in the bank net of amounts owed to a third party after selling a portion of the claims.

Guidance Calls for Continued Aerie Strength For the second quarter, the company expects comparable sales growth in the mid- to high-single-digit range. Mathias said Aerie and OFFLINE are expected to continue growing in the high teens to low 20% range, while American Eagle is expected to be flat to down low single digits.

The company expects second-quarter operating income of $45 million to $50 million, including the $20 million tariff headwind. SG&A is expected to rise in the mid-teens, primarily due to continued advertising investment.

For the full year, American Eagle Outfitters expects operating profit of $390 million to $410 million, based on consolidated comparable sales growth in the mid-single-digit range. Mathias said the company expects capital expenditures of $250 million to $260 million.

In the back half of the year, Mathias said the company expects American Eagle comparable sales in the low single-digit range, while Aerie is expected to moderate to high single-digit to low double-digit growth. He said that mix would support mid-single-digit comparable sales growth for the total portfolio.

Capital Returns and Store Plans The company returned $74 million to shareholders in the quarter, including $21 million through its quarterly dividend and $53 million through repurchases of 3 million shares. Capital expenditures totaled $61 million. American Eagle Outfitters ended the quarter with $103 million in cash and approximately $620 million of total liquidity, including its revolver.

Schottenstein also highlighted the opening of the company’s West Coast distribution center in Phoenix, which went live in early May. He said the facility supports efforts to optimize the distribution network, improve inventory placement and give customers more options for receiving products.

On stores, Mathias said the company still expects roughly 25 net closures for the American Eagle brand this year, along with about 40 Aerie and OFFLINE openings. He said the company is planning around 80 American Eagle remodel projects, with the program nearing completion after potentially one more year.

Schottenstein said the company remains optimistic despite a fluid retail environment. “We think American Eagle’s positioned very well,” he said, adding that the brand offers “great value” and “great quality” to consumers.

About American Eagle Outfitters NYSE: AEOAmerican Eagle Outfitters, Inc NYSE: AEO is a leading American specialty retailer offering apparel, accessories and personal care products for men and women. The company's flagship brand, American Eagle, focuses on casualwear including denim, tops, outerwear and accessories targeted primarily at teens and young adults. In addition to its core apparel lines, the company operates the Aerie brand of intimates, loungewear and swimwear, which has gained recognition for its body-positive marketing and inclusive sizing.

American Eagle Outfitters conducts business through a combination of over 900 brick-and-mortar stores in North America and Greater China, complemented by a growing e-commerce platform that serves customers around the globe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in American Eagle Outfitters Right Now?Before you consider American Eagle Outfitters, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and American Eagle Outfitters wasn't on the list.

While American Eagle Outfitters currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

American Eagle Outfitters (AEO - Free Report) reported $1.2 billion in revenue for the quarter ended April 2026, representing a year-over-year increase of 9.7%. EPS of $0.14 for the same period compares to -$0.29 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.18 billion, representing a surprise of +0.94%. The company delivered an EPS surprise of +25.34%, with the consensus EPS estimate being $0.11.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how American Eagle performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Number of stores - AE Brand: 804 compared to the 801 average estimate based on three analysts.Number of stores - Aerie stand-alone (incl. OFFL/NE): 335 compared to the 341 average estimate based on three analysts.Number of stores - Total (EOP): 1,170 compared to the 1,175 average estimate based on three analysts.Gross square footage - Total: 7.22 Msq ft compared to the 7.33 Msq ft average estimate based on two analysts.Comparable store sales- American Eagle Outfitters: -2% versus 2.6% estimated by two analysts on average.Comparable store sales: 8% versus 8.9% estimated by two analysts on average.Comparable store sales - Aerie: 25% versus 21.2% estimated by two analysts on average.Total net revenue- American Eagle: $678.48 million compared to the $717.34 million average estimate based on three analysts. The reported number represents a change of -2.2% year over year.Total net revenue- Aerie: $480.83 million compared to the $434.27 million average estimate based on three analysts. The reported number represents a change of +33.6% year over year.View all Key Company Metrics for American Eagle here>>>

Shares of American Eagle have returned +2.6% over the past month versus the Zacks S&P 500 composite's +5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

SummaryCompaniesGap cuts annual sales forecast, American Eagle maintains outlookAnalysts highlight Gap's Old Navy and American Eagle brands as key weak spotsGap shares fall 17%, American Eagle down 12%May 29 - Shares of Gap (GAP.N), opens new tab and American Eagle Outfitters (AEO.N), opens new tab tumbled over ‌12% on Friday after both retailers issued weak forecasts, signaling deepening pressure on consumer discretionary spending.

The Old Navy parent cut its annual sales forecast as it works through a turnaround, while American Eagle kept its forecasts intact but cautioned on near-term gross margins, with ​both flagging weakness in certain women's apparel categories.

The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.

Gap stock is on track for its worst day in ​a year. Broader pressure was also felt in Europe, with Stockholm-listed shares of H&M (HMb.ST), opens new tab ⁠falling about 1% earlier on Friday.

The results underscore a widening split in consumer spending, with record-low sentiment driven by ​the Iran war forcing lower-income households to cut back, even as higher-income shoppers remain selectively willing to spend.

Earlier this ​week, Abercrombie & Fitch (ANF.N), opens new tab and Bath & Body Works (BBWI.N), opens new tab posted strong quarterly results, indicating continued appetite from American shoppers for affordable indulgence.

"(Gap's) moderated outlook is disappointing against the backdrop of a relatively resilient consumer through the first quarter of the fiscal year, broadly speaking," Telsey Advisory ​analyst Dana Telsey said.

Pressure at Gap was centered around Old Navy, where seasonal women's apparel, including dresses, failed to ​connect with shoppers, analysts said. BTIG analysts called Old Navy the "key swing factor."

However, some analysts said that the company's push into ‌the ⁠higher-margin beauty category could help Gap in the longer term.

Item 1 of 3 American Eagle clothing is seen at their store at the Woodbury Common Premium Outlets in Central Valley, New York, U.S., February 15, 2022. REUTERS/Andrew Kelly

[1/3]American Eagle clothing is seen at their store at the Woodbury Common Premium Outlets in Central Valley, New York, U.S., February 15, 2022. REUTERS/Andrew Kelly Purchase Licensing Rights, opens new tab

American Eagle slumps sharply while Gap underperforms and broader apparel and market indices post modest gains.American Eagle also faced challenges as the strength at Aerie failed to offset weakness at its core brand, with women’s bottoms hurt by shifting trends and a colder spring.

The company recently launched another campaign with actor Sydney Sweeney to attract Gen Z shoppers, a year after a viral and ​controversial ad featuring Sweeney fueled ​a stock rally.

Barclays analysts, ⁠however, cautioned that repeating last year's success may be difficult even as marketing spending is expected to recur in the current quarter.

The American Eagle brand continues to lag ​Aerie by a wide margin, challenging expectations of improvement, despite the brand's plans to ​correct its ⁠women's assortment for the back-to-school season, Telsey added.

Sales growth at Gap’s Old Navy, American Eagle’s namesake brand coolsGap currently trades at 10.30 times its estimated earnings for the next 12 months, compared with 9.70 times for American Eagle and 7.43 times for Abercrombie & Fitch (ANF.N), opens new tab, according to LSEG data.

American Eagle fell ⁠as ​much as 19% on Friday, adding to 2026 losses of 32%. ​Gap was down about 2% this year as of Thursday's close.

Reporting by Akriti Shah, Siddarth S and Neil J Kanatt in Bengaluru; Editing by Vijay Kishore

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Akrit Shah is a broker research and markets correspondent at Reuters, reporting on brokerage firms, equity research, market trends, and corporate earnings across the U.S. She has several years of experience in journalism and digital media, and previously held roles in digital marketing and social media. Akrit has trained extensively in financial reporting at Reuters and holds certifications in digital marketing. She is a Javaphile who enjoys writing poems and quotes.